Epitope labeling and methods for detecting, capturing, and / or purifying labeled peptides

By using a complex formed by BC2-nanobody and BC2T peptide sequence, the problems of low affinity and nonspecificity in peptide detection and purification in existing technologies are solved, achieving efficient, specific and reliable peptide detection and purification.

CN108291229BActive Publication Date: 2026-11-10PROTEINTECH GERMANY GMBH +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN201680066577.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2015-11-16
Filing Date
2016-11-15
Publication Date
2026-11-10
Estimated Expiration
2036-11-15

AI Technical Summary

Technical Problem

Existing immunoaffinity detection and capture systems suffer from low affinity, nonspecific interactions, batch-to-batch variability, and reduced antibody function, and are particularly inefficient in detecting and purifying peptides of interest.

Method used

Using BC2-nanobodies as epitope-specific antibodies, a high-affinity, specific, and reproducible complex is formed with the BC2T peptide sequence for the detection and purification of labeled peptides, combined with a protein purification method under harsh conditions.

Benefits of technology

It enables efficient, specific and reliable peptide detection and purification, and can robustly purify recombinant proteins under mild or harsh conditions, reducing false positive results and improving detection accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN108291229B_ABST
    Figure CN108291229B_ABST
Patent Text Reader

Abstract

This invention relates to novel epitopes that can be used as markers for methods of rapid and efficient characterization, purification, and subcellular localization of peptides of interest, including the marker. The markers are specifically recognized by epitope-specific antibodies and can be used to detect, capture, quantify, and / or purify peptides of interest using the epitope markers of this invention.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of biomedical research, biochemistry, and cell biology. Novel epitopes are presented that can be used as markers for the rapid and efficient characterization, purification, and in vivo localization of peptides of interest comprising the marker. The markers are specifically recognized by epitope-specific antibodies, allowing for antibody-marker interactions. Background Technology

[0002] In the post-genomics era, the field of proteomics has made significant progress. Affinity-based analysis is indispensable for a wide range of applications from mass spectrometry to high-content imaging. Affinity-based analysis relies on the detection of protein-protein interactions (PPIs) between receptors and ligands, such as antibodies and antigens. In the case of monitoring antigen-antibody interactions, the analysis is also known as immunoaffinity analysis. Immunoaffinity analysis is a selective method used to test the identity, quantity, and / or location of peptides of interest. However, there are situations where no suitable antibody is available. The drawbacks of immunoaffinity-based analysis can be overcome by a method called "epitope tagging," in which proteins are labeled using epitopes—the binding portion of antigen proteins.

[0003] Labeled epitopes are a technique that uses genetic engineering to fuse known epitopes into recombinant proteins. By selecting epitopes for which antibodies are available, this technique allows the detection of proteins for which no antibodies are available. Since the late 1980s, labeled epitopes have become a standard molecular genetics method for enabling the rapid and efficient characterization, purification, and in vivo localization of protein products from cloned genes.

[0004] In the early days of proteomics, the first commercially available tags were initially designed for protein purification. Examples of these early tags were FLAG, 6×HIS, and the glutathione S-transferase (GST) system. The 6×HIS tag relies on metal affinity, and the GST system relies on the affinity of GST for glutathione. FLAG was one of the first commercially available epitope tags.

[0005] Later, the discovery of fluorescent reporter molecules such as green fluorescent protein (GFP) made it possible to detect proteins within cells without the need for a second reagent. In this case, the full-length protein sequence of GFP is used to label the protein of interest, causing the labeled protein of interest to fluoresce.

[0006] However, the problem with labeling full-length proteins, such as GST maltose-binding protein (MBP) or GFP, is that they sometimes spatially interfere with the localization or folding of subcellular proteins, which may compromise or disable the native function of the protein being analyzed.

[0007] Therefore, numerous small peptide-based epitope markers have been developed, such as c-myc, V5, HA, CBP, or FLAG. These markers have a synthetic origin (FLAG) or are derived from viral (HA, V5) or endogenous mammalian (c-myc, CBP) proteins. They are characterized by a size of 8–26 amino acid residues and are detected by classic IgG (polyclonal or monoclonal) assays. One problem with markers derived from endogenous proteins is the fact that marker-specific antibodies often also bind to the endogenous protein. If the interaction between the marker and the antibody is not specific, the analysis may yield false positives. The analysis will be inefficient due to competition between the marker protein, which acts as a binding partner for the antibody, and the endogenous protein.

[0008] Although many immunoaffinity capture systems are available using labeled specific antibodies, serious problems remain due to low affinity binding, nonspecific interactions, batch-to-batch variability, or reduced antibody function after covalent coupling to a solid surface.

[0009] In addition, a specific problem with known immunoaffinity detection and / or capture systems is that they rely on conventional antibodies evolved from the vertebrate immune system to detect proteins that label epitopes.

[0010] Therefore, the objective of this invention is to provide an immunoaffinity detection and / or capture system characterized by high affinity, specificity, and reproducibility.

[0011] Furthermore, an objective of this invention is to provide epitope markers that can interact specifically, reliably, reproducibly, and with high affinity with epitope-specific antibodies. A further objective of this invention is to provide essential components of immunoaffinity-based assays suitable for the reliable, specific, and efficient detection of peptides of interest, which can be used, for example, for cell imaging or direct antigen detection.

[0012] A further objective of the present invention is to provide essential components of an immunoaffinity-based assay suitable for reliably, specifically, and efficiently purifying peptides of interest.

[0013] Furthermore, the objective of this invention is to provide a system for capture and / or detection, specifically a system that can be used for different types of analysis, for combined analysis through microscopic and biochemical studies, etc.

[0014] A further goal is to provide a robust purification method for recombinant proteins that allows for the use of non-denaturing or denaturing conditions. Attached Figure Description

[0015] The invention will be further described with reference to the following figures.

[0016] Figure 1 The structural analysis of BC2-nanobody (BC2-Nb) and BC2-Nb / BC2T complex is shown.

[0017] (a) shows the BC2-Nb / BC2T backbone interaction. The BC2-peptide (BC2T) (pink) folds into a β-chain, which is part of the β-sheet structure formed by complementarity-determining region 3 (CDR3, blue) and framework regions 2 and 3 (grey). Thirteen backbone-backbone hydrogen bonds are shown (black dashed lines), one of which is water-mediated (red sphere). CDR3 contributes to eight of these interactions, and the framework regions contribute to five. CDR1 (pale yellow) and CDR2 (yellow) do not participate in the binding.

[0018] (b) illustrates the so-called “headlock” interaction. The charge-mediated interaction between Arg106 in CDR3 (blue) and Glu44 in FR2 stabilizes the BC2-Nb / BC2T complex. These amino acid side chains reachover the peptide (pink), forming salt bridges that lock the peptide into its binding site.

[0019] (c) shows the specific BC2-Nb / BC2T interaction. In addition to skeletal interactions, a small number of side-chain-mediated interactions generate specificity for the BC2T peptide sequence. BC2T residue W10 participates in the CH-π interaction with Cys50 (dashed line). Water molecules (red spheres) are bound to peptide amino acids S8 (pink), Tyr109, two carbonyl groups, and one amino group. Charge-mediated interactions between the side chains of Arg106 (CDR3) and Glu44 (FR2), which cross the peptide, are also shown.

[0020] Figure 2 The identification of residues mediating BC2T binding specificity was demonstrated.

[0021] Using BC2-Nb (black stripes) immobilized on agarose, BC2-Nb R106S (Light gray) and BC2-Nb R106E(Dark gray) Cultured BC2T positional sequence variant library (n=3). After precipitation, the supernatant was subjected to liquid chromatography followed by mass spectrometry. Specifically, the sequence variants in the precipitate were identified by calculating the signal ratios generated by the peptides in the supernatant of BC2-Nb or the supernatant of the indicated mutant and non-BC2T-related control Nb (GFP-specific Nb). (a) BC2T is shown. R3X (b)BC2T A6X (c)BC2T S8X and (d)BC2T W10X Results of the sequence variant library (see Table 1 for complete results). The altered position is indicated as X in the BC2T sequence. Amino acids were grouped according to the physicochemical properties of their side chains: nonpolar, polar, and charged. γ-aminobutyric acid was used instead of cysteine ​​in the library synthesis. The mean and standard deviation (sd; error bars) of three independent experiments are shown.

[0022] Figure 3 The paper demonstrates the one-step purification of BC2-labeled proteins using BC2 nanotrap.

[0023] (a) For immunoprecipitation, BC2-Nb (BC2 nanotrap) immobilized on agarose was used to cultivate cells expressing C-terminal BC2-labeled (GFP) cells. BC2T Soluble protein fractions of bacterial lysate containing GFP or GFP alone. Input (I), unbound (NB), and bound fractions (B) were separated by SDS-PAGE and visualized by Coomassie blue (top) or by immunoblotting (bottom).

[0024] (b) BC2 nanotrap efficiently binds to its epitopes under harsh conditions. GFP derived from bacterial extracts. BC2T Incubation was performed with increasing concentrations of SDS (0–2%), urea (0–4 M), or guanidine hydrochloride (0–3 M) and precipitation was observed as described in (a). The input (I) and the fractions of binding are shown under the indicated conditions.

[0025] (c) BC2-labeled proteins are efficiently released using alkaline pH or peptide elution. GFP bound to BC2 nanotraps. BC2T The samples were subjected to elution with sodium thiocyanate (NaSCN, 1–3 M), acidic elution (0.2 M glycine, pH 1–2.5), alkaline elution (pH 10–12), or peptide elution (0–1 mM). Aliquots of the released (R) and bound (B) fractions were analyzed by immunoblotting with anti-GFP antibody.

[0026] (d) BC2 nanotraps bind to BC2-labeled proteins derived from human cell lysates, regardless of whether the BC2 label is located at the N-terminus or C-terminus. For immunoprecipitated BC2-labeled proteins, as described in (a), expression was cultured using BC2 nanotraps. BC2T eGFP, eGFP BC2T Soluble protein fractions of HEK293T cells containing eGFP alone. Input (I), unbound (NB), and bound fractions (B) were separated by SDS-PAGE and visualized by Coomassie blue staining (top) or by immunoblotting analysis (bottom).

[0027] Figure 4 The results of immunocytochemical experiments using fluorescently labeled BC2 nanobodies are shown.

[0028] (a) A schematic diagram showing the BC2-tagged fusion protein and fluorescently labeled BC2-Nb used for colocalization studies. The BC2T sequence was genetically fused into mCherry-Vimentin (mCherry-VIM). BC2T ) and eGFP-PCNA (eGFP-PCNA) BC2T The C-terminus of ).

[0029] (b) Immobilization of ectopic expression of mCherry-VIM using methanol or PFA, respectively. BC2T or eGFP-PCNA BC2T HeLa cells were then stained with indicated fluorescently labeled BC2-Nb and DAPI. Scale bar 25 μm.

[0030] Figure 5 The structures of uncoordinated BC2-Nb and the corresponding BC2-Nb / BC2T complexes are shown.

[0031] (a) shows a banded diagram of the uncoordinated BC2-Nb structure. The four cysteine ​​residues that form the two disulfide bonds are labeled. CDR3 is highlighted in orange, contributing to the contact of the peptide in the coordinated structure and undergoing amino acid flipping after binding.

[0032] (b) shows the superposition of uncoordinated and coordinated BC2-Nb structures. A comparison of the two structures reveals a 180-degree inversion of the two amino acids. In the BC2-Nb structure, Arg106 interacts with the carbonyl group of Glu108, and Tyr107 participates in a cation π-interaction with Arg45 (orange band trace). The β-carbon of Arg106 is oriented towards Nb, and Tyr107 is oriented away from Nb. In the peptide-bound complex structure, this is reversed (blue band trace). Arg106 participates in “headlock” binding, and Tyr107 forms a hydrogen bond with the carbonyl group of Arg104.

[0033] Figure 6 A schematic diagram showing the interaction between BC2-peptide and BC2-Nb is presented.

[0034] The BC2-peptide is shown with pink side chains. Its acetylated N-terminus is at the top and its amidated C-terminus is at the bottom. All polar interactions within the matrix are represented by black dashed lines, where for the backbone, their interacting partners from BC2-Nb are green, and for side-chain interactions, they are yellow. Water molecules are shown in blue. The relevant hydrophobic interactions within are represented by gray dashed lines.

[0035] Figure 7 The mutation of the headlock motif resulted in an increased off-rate of the BC2 nanobody. For affinity measurements based on surface plasmon resonance spectroscopy (SPR), GFP with a C-terminal BC2-label (GFP...) was... BC2T GFP(a) or GFP(d) alone was immobilized on a CM5-chip. This was achieved by injecting six concentrations of BC2-Nb(a), BC2-Nb(d), and GFP(c) in the range of 8 nM to 250 nM. R106S (b) or BC2-Nb R106E (c) Kinetic measurements were performed. The obtained datasets were evaluated using a 1:1 Langmuir binding model with mass transfer. As a control, only BC2-Nb binding to GFP was tested (d). Table 3 summarizes the obtained data according to the dissociation constant (K). D The affinity expressed by ) and the association (k) measured against BC2-Nb and the corresponding mutants. on ) and dissociation rate constant (k off ).

[0036] Figure 8 The study demonstrated that proteins captured by BC2 nanotraps can be eluted under natural conditions.

[0037] GFP derived from bacterial lysate BC2T Bound by BC2 nanotrap and subjected to use such Figure 3 Elution under the buffer conditions described in section c. Visualization and quantification of GFP release using a laser scanner. BC2T The fluorescence signal intensity. The figure above shows the eluted GFP. BC2T Fluorescence intensity compared to completely lysed products. The following figure shows the quantification of GFP-fluorescence obtained under different elution conditions. GFP-fluorescence obtained from untreated lysed products was set as 1. The mean and sd (error bars) (R1–R3) of three independent experiments are shown.

[0038] Figure 9 This demonstrates that BC2-Nb is functional for immunoprecipitation and detection of BC2-labeled proteins.

[0039] (a) For immunoprecipitation, BC2 nanotrap was used to cultivate eGFP-PCNA expressing eGFP-PCNA (control) or BC2-labeled eGFP-PCNA (eGFP-PCNA). BC2T (Left image) or mCherry-Vimentin (mCherry-VIM, control) or BC2-labeled mCherry-VIM (mCherry-VIM) BC2T Soluble protein fractions from HEK293T cells. Input (I), unbound (NB), and bound fractions (B) were separated by SDS-PAGE and visualized by Western blot analysis using anti-PCNA or anti-Vimentin antibodies (top panel). As a control, the blot was detected using anti-GAPDH antibody (bottom panel).

[0040] (b) For BC2-Nb (BC2-Nb) labeled with fluorescence AF488 For protein blotting detection, the input fractions (as shown in (a)) underwent SDS-PAGE and immunoblotting. BC2-Nb was used. 488 The protein blot was then probed using either anti-PCNA (left image) or anti-Vimentin (right image) antibodies. As a control, anti-GAPDH antibody (bottom image) was used to probe the blot.

[0041] (c) Showing that, compared to overexpressed BC2-labeled proteins, BC2 nanotraps precipitate only small amounts of endogenous β-linkin. For example... Figure 3 The sample described in d(a) underwent immunoblotting analysis using an anti-β-netin antibody. The arrow indicates a β-netin-specific signal.

[0042] Figure 10 The results obtained by immunocytochemistry using fluorescently labeled BC2 nanobodies are shown.

[0043] (a) shows the mCherry-Vimentin protein. BC2T With BC2-Nb AF488 Confocal imaging. Methanol was used to immobilize ectopically expressed mCherry-VIM. BC2T HeLa cells were then stained with fluorescently labeled BC2-Nb and DAPI. Figure 4 The image in the lower left corner of the upper part of figure b shows the maximum projected image of the cell (z-stack of 7 planes). Scale bar: 10 μm.

[0044] (b) shows BC2-Nb AF488 and BC2-NbATTO647 Specificity was determined. HeLa cells ectopically expressing unlabeled mCherry-VIM or eGFP-PCNA were fixed with methanol or PFA, respectively, and stained with indicated fluorescently labeled BC2-Nb and DAPI. Scale bar 25 μm.

[0045] Figure 11 A variant of the BC2 marker of the present invention is shown. The original BC2T sequence (PDRKAAVSHWQQ; SEQ ID NO:4) is modified in 50% of all positions to produce the sequence PVRSALSQWSS (BC2T mutant; SEQ ID NO:5).

[0046] Both the original and modified versions of the BC2 label were fused to the C-terminus of GFP. GFP without the BC2 label was used as a negative control. The protein was expressed in *E. coli*. Lysate was prepared and 100 μg of total lysate was immunoprecipitated using BC2 nanobodies immobilized on agarose. The input (I), unbound (NB), and bound (B) fractions were analyzed by SDS-PAGE followed by Coomassie staining (top) or by immunoblotting using anti-GFP antibody (bottom).

[0047] Figure 12 The length variations of the BC2 marker are shown. The original BC2T sequence (PDRKAAVSHWQQ; SEQ ID NO:4) was shortened to produce the sequences PDRKAAVSHW (BC2T-10; SEQ ID NO:14) and RKAAVSHW (BC2T-8; SEQ ID NO:3). The shortened and original versions of the marker were fused to the C-terminus of GFP (GFP-BC2T-10; GFP-BC2T-8, GFP-BC2T). GFP without the BC2 marker was used as a negative control. The protein was expressed in *E. coli*. Lysate was prepared and 100 μg of total lysate was immunoprecipitated using BC2 nanobodies immobilized on agarose beads. The input fractions (I), unbound (NB), and bound (B) were analyzed by SDS-PAGE followed by Western blotting with an anti-GFP antibody. The results showed that the BC2T-10 sequence (PDRKAAVSHW; SEQ ID NO:14) or BC2T-8 sequence (RKAAVSHW) used as C-terminal markers were efficiently recognized by epitope-specific BC2 nanobodies, just like the original 12 amino acids of BC2T (PDRKAAVSHWQQ).

[0048] Figure 13Two variants of the BC2 marker with improved binding affinity compared to the wild-type BC2 marker are shown. Affinity measurements based on biolayer interferometry (BLI) were used to evaluate two improved variants of the original BC2T sequence (a: PDRVRAVSHWSS, pTag1 SEQ ID NO:33; b: ADRVRAVSHWSS, pTag2 SEQ ID NO:34) compared to the original BC2T sequence (c: BC2T SEQ ID NO:4). BC2T and its improved variants were synthesized as peptides with N-terminal biotin attached via an ethylene glycol linker and immobilized on a streptavidin biosensor. Binding kinetics were analyzed by culturing the immobilized peptides in 4–5 concentrations of BC2-Nb (5–50 nM) and evaluated using a 1:1 binding model. The obtained dissociation constants (K0) are summarized in Table 5. D ), association (k on ) and dissociation rate constant (k off ).

[0049] Figure 14 The application of two improved variants of the BC2 marker in protein purification and immunoprecipitation is shown.

[0050] (a) Protein purification: BC2 nanotraps were cultured using mCherry protein samples labeled with the original BC2 tag BC2T (SEQ ID NO:4) or its modified variants (pTag1 SEQ ID NO:33 and pTag2 SEQ ID NO:34) at the N-terminus or C-terminus. The bound proteins were then eluted with the corresponding free peptides at a concentration of 100 μM. The fractions of input (I), unbound protein (NB), protein released by peptide elution (R), and protein still bound after elution (B) were analyzed using SDS-PAGE and Coomassie staining.

[0051] (b) Immunoprecipitation: BC2 nanotraps were used to precipitate mCherry proteins with the BC2-tagged variant pTag1 SEQ ID NO:33 fused to N-terminus of lysate from human cell line HEK293T, the insect cell line High5 (Trichoplusia ni), and yeast (Saccharomyces cerevisiae). The fractionation of input (I) and bound proteins (B) was analyzed using SDS-PAGE and Coomassie staining.

[0052] definition

[0053] Throughout this specification and the claims, numerous terms will be used, which should be defined to have the following meanings:

[0054] The terms "epitope peptide" or "epitope marker" should refer to the peptide sequence of the present invention used as a marker; the two terms are used interchangeably. The epitope peptide of the present invention is any peptide comprising at least the 8 amino acid sequence defined in SEQ ID NO:1 as claimed in claim 1, wherein, when the isolated epitope peptide comprises at least 9 amino acids, it does not include the amino acid sequence (RKAAVSHW) as defined by SEQ ID NO:3. The epitope peptide or epitope marker may be an isolated sequence or may be part of a sequence.

[0055] The term "peptide" refers to any type of polypeptide or protein and includes any amino acid sequence in which amino acids are linked by peptide bonds, such as an amino acid sequence of at least 10 amino acids in length, provided that the epitope label and the construct of the polypeptide are not β-linkin. The term polypeptide is used very generally in this application and should also include peptides, such as oligopeptides. The terms polypeptide and protein are used interchangeably.

[0056] The terms "peptide of interest" or "protein of interest" should refer to any type of polypeptide or protein having a particular function or property, such as physiologically active molecules, and include all structural and sequence variants with the desired property or function. Specifically, the term should cover any type of peptide and protein, as well as fusion proteins. The two terms are used interchangeably.

[0057] The terms "fusion protein" or "fusion polypeptide" should refer to a protein or polypeptide formed by the joining of two or more polypeptides, or at least one polypeptide and at least one peptide, or at least one polypeptide and at least one oligopeptide. For example, a "fusion protein" can refer to a polypeptide comprising the amino acid sequence of a protein with an epitope peptide fused to it. A fusion protein or fusion polypeptide may comprise one or more polypeptides and one or more epitope peptides. Moreover, the fusion peptide may be joined via a bridge or linker sequence. The epitope peptide is preferably fused to the N- or C-terminus of the amino acid sequence of the protein—directly or via a linker molecule.

[0058] A linker is any unit that connects two parts of a molecule, such as two nucleic acids, two peptides or proteins, a labeled and a protein of interest, or a nucleotide, peptide or protein, and a carrier. Any unit known for this purpose may be used, as long as it does not interfere with the function of the molecule. When the connected members are nucleic acids, the linker may consist of nucleotides, for example, 3 to 150 nucleotides, or when at least one of the two parts is a peptide or protein, or another bridging molecule, the linker may be a single amino acid or an amino acid sequence of 2 to 50 amino acids.

[0059] Variants of the epitope peptides of the present invention are peptides comprising at least eight amino acids having amino acids 1, 4, 6, and 8 of SEQ ID NO:3 at positions 1, 4, 6, and 8, while the remaining amino acids may be amino acids of SEQ ID NO:3, and at least one of those may be another amino acid similar in size, polarity, and / or charge to the “original” amino acid of SEQ ID NO:3. In other words, the term “variant” as used herein refers to a sequence derived from or corresponding to SEQ ID NO:3, wherein at least 12.5% ​​and up to 25, or 37.5, or 50% of the amino acids are replaced by substitutions such as conservative substitutions. For example, lysine may also be replaced by serine without altering the function of the peptide. Variants of the present invention may be epitope peptides as defined above, wherein four of the eight amino acids of the sequence of SEQ ID NO:3 may be substituted without substantially altering the function of the peptide. Variants of the epitope peptides of the present invention comprising eight amino acid residues with three conservative substitutions—producing variants with 37.5% conservative substitutions—have been shown to be active in the examples.

[0060] The epitope markers of this invention located at the C-terminus or N-terminus mean that no other amino acid residues derived from the sequence of the polypeptide of interest precede the epitope marker sequence at the N-terminus or follow the epitope marker sequence at the C-terminus. However, sequences not derived from the original sequence of the polypeptide of interest, such as further markers or linker sequences, may follow or precede the C- or N-terminal markers of this invention.

[0061] When used in this application, the term "purification" should refer to any type of physical separation of a chemical or biochemical entity of interest from a material, such as a biochemical material. An example is the purification of peptides from biochemical substances such as tissues or broths. The purified entity may also be referred to as an isolate. Protein or peptide purification may include one step or a series of steps to isolate or enrich one or more proteins from a sample. Purification is essential for characterizing the function, structure, and interactions of the proteins of interest. Purification may include separating a protein from the non-protein portion of a sample or separating the desired protein from other proteins. The result of purification may be an isolated protein or a sample in which peptides are enriched. In this application, the term "purification" covers any type of separation and encompasses both separation and enrichment.

[0062] The term "sample" refers to a sample or quantity used in any type of assay or purification method. A sample includes a marker of interest and / or a protein, and may be liquid or solid. In the context of this invention, a sample can typically be a complex mixture including the protein of interest, such as cells, tissues, or cell lysates. A sample can also be a supernatant obtained by liquid centrifugation including cells, where the cells are capable of secreting the protein of interest into the liquid. A sample can also be a sample of any type of bodily fluid, such as blood, urine, liquid, sweat, tears, etc.

[0063] The term "second binding pair" refers to a compound that can specifically or nonspecifically bind to a labeled polypeptide, an epitope-specific affinity ligand such as an antibody, or a complex formed by both as a first binding pair, either directly or via a unit provided at the polypeptide or affinity ligand such as an antibody. An example of a binding pair is the constant portion of an epitope-specific antibody and an Fc-specific antibody. Another example of a binding pair is the biotinylate portion present on a labeled polypeptide or epitope-specific antibody and streptavidin. A further example of a second binding pair is an antibody targeting a complex. Second binding pairs can be used to separate and / or detect complexes. For this purpose, second binding pairs can carry immobilizable groups, detectable groups, etc. Summary of the Invention

[0064] This invention relates to the epitope peptide sequence defined in SEQ ID NO:1.

[0065] Surprisingly, peptide sequences comprising at least eight amino acids (RKAAVSHW) or variants thereof, as SEQ ID NO:3, have been found to be useful as epitope markers. This amino acid sequence is sufficient for specific binding because its antibody affinity for the epitope is high enough to ensure specific and reliable interaction with the marker. Furthermore, the capture and / or detection systems for epitope peptides based on the present invention have been found to possess highly desirable properties. For example, proteins labeled with epitopes have been shown to bind at ~1.4 nM K. D When bound by an epitope-specific antibody, it exhibits an affinity that is ~10-100 times higher than that of existing systems such as FLAG, HA, c-myc, or nanobody-derived EPEA-systems. The epitope peptides of this invention are highly versatile; they can be used as C-terminal or N-terminal labels and exhibit strong binding to the corresponding antibodies under mild or harsh conditions. One or more labels can be used, which can be the same or different, provided that at least one of the labels is an epitope label of this invention, and they can be located at different ends of the polypeptide or arranged in tandem or any other order. Specifically, the detection and / or capture systems of this invention typically exhibit strong affinity and binding efficiency due to their unique binding properties.

[0066] Moreover, it was surprisingly found that only four amino acids in SEQ ID NO:3 (referring to the amino acid residues in SEQ ID NO:3, R at position 1, A at position 4, S at position 6, and W at position 8) are required for the specific binding of the label-specific antibody, and the remaining positions can be substituted, for example, by another amino acid that is similar to the "original" amino acid in size, polarity, and / or charge, and preferably by conservative substitutions, without significantly negatively affecting binding specificity and affinity. Epitope tags—which include substitutions, preferably conservative substitutions, at up to 50% of the amino acids included in the peptides defined in SEQ ID NO:4—have been found to still ensure efficient and reliable interaction between the label-specific antibody and the labeled protein. Peptides with additional amino acids at one or both ends have also been found to provide efficient and reliable interaction with peptide-specific antibodies. As an example, a labeled or epitope peptide modified with the amino acid sequence PVRSALSQWSS (SEQ ID NO:5) has been used for efficient purification of labeled GFP proteins (see [link to documentation]). Figure 11 Further examples of modified labeled or epitope peptides have an amino acid sequence as defined by SEQ ID NO:33 (PDRVRAVSHWSS) or an amino acid sequence as defined by SEQ ID NO:34 (ADRVRAVSHWSS).

[0067] It has been found that the epitope markers of the present invention can further include amino acids flanked by a central marker sequence. While marker sequences longer than 25 amino acids can be used, it is advantageous to provide small markers to minimize interference with the subcellular localization, folding, or function of the fused labeled peptide or protein; therefore, the epitope peptides of the present invention including the marker should not comprise more than 25 amino acids.

[0068] Therefore, the epitope peptide or label of the present invention has 8 to 25 amino acids, preferably consisting of 8 to 25 amino acids, wherein the amino acid sequence includes the sequence defined in SEQ ID NO:1 (RX4X5AX7SX9W).

[0069] Where X4 can be K or a permutation;

[0070] Where X5 can be A or R, or a conservative permutation of A or R;

[0071] Where X7 can be V or a conservative permutation of V, and

[0072] Where X9 can be H or a conservative permutation of H;

[0073] When the isolated epitope peptide comprises at least 9 amino acids, it does not include the amino acid sequence (RKAAVSHW) defined by SEQ ID NO:3.

[0074] In a preferred embodiment, X4 can be a conservative substitution of K or serine.

[0075] In a preferred embodiment, the epitope peptide of the present invention has 12 to 25 amino acids, preferably consisting of 12 to 25 amino acids, wherein the amino acid sequence includes the sequence defined in SEQ ID NO:32 (X1X2RX4X5AX7SX9WX). 11 X 12 ),

[0076] Where X1 can be P or A;

[0077] Where X2 can be D or a conservative permutation of D;

[0078] Where X4 can be K or a permutation;

[0079] Where X5 can be A or R, or a conservative permutation of A or R;

[0080] Where X7 can be V or a conservative permutation of V;

[0081] Where X9 can be a conservative permutation of H or H; and

[0082] Where X 11 and X 12 It can be a conservative permutation of Q or Q;

[0083] The isolated epitope peptides do not include the amino acid sequence (RKAAVSHW) defined by SEQ ID NO:3.

[0084] In a preferred embodiment, X4 can be a conservative substitution of K or serine.

[0085] "Conservative substitution" refers to the substitution of one amino acid for another, where the substitution results in a silent change. This means that one or more amino acid residues within the epitope peptide sequence of this invention can be substituted by another amino acid of similar polarity that acts as a functional equivalent. The substitution of amino acids within the sequence can be selected from other members of the same class of amino acids (i.e., conservative substitution). For example, a polar amino acid can be substituted by another polar amino acid, a positively or negatively charged amino acid can be substituted by another positively or negatively charged amino acid, and so on. For example, the types of amino acids are nonpolar (hydrophobic) amino acids, including alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids, including glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids, including arginine, lysine, and histidine; and negatively charged (acidic) amino acids, including aspartic acid and glutamic acid.

[0086] The epitope peptides of the present invention are provided in isolated form, meaning they are not contained in an animal or human body. Epitope peptides may be provided as isolated peptides or may be used in conjugated, linked, bound, or coupled forms, such as as fusion proteins, wherein at least one epitope is fused to a polypeptide, specifically, the protein or polypeptide of interest; or as constructs comprising at least one epitope of the present invention and a polypeptide, optionally linked or coupled by a linker, spacer region, or other linking element. Linkers, spacer regions, or other linking elements may be any sequence known in the art. They may be, for example, sequences providing cleavage sites or may be precisely spacer regions, i.e., components regulating the distance between the epitope and the polypeptide, or linking elements contributing the desired function.

[0087] Surprisingly, this epitope peptide was found to be highly efficient and reliable as an epitope marker, which interacts specifically and efficiently with marker-specific antibodies.

[0088] "Labeled epitopes" are techniques in which a known epitope is fused into a peptide, such as a recombinant protein, for example, through genetic engineering. The epitope label can be used in combination with an antibody specific to that epitope for the detection of the peptide, such as a protein of interest. For an epitope label to be useful, the peptide should provide a region for selective binding to a specific antibody, the labeled region should be available for binding even if the label is attached to or fused to the peptide, and non-specific binding should be avoided as much as possible. The binding between the epitope label and the corresponding antibody should be strong, reliable, and selective. By selecting a suitable combination of epitope label and corresponding antibody, this technique makes it possible to detect proteins for which no antibody is available. This is particularly useful for characterizing newly discovered proteins and proteins with low immunogenicity. This invention provides a system comprising an epitope and antibody pair that can be used in a wide range of experimental applications, such as Western blotting, immunoprecipitation, immunohistochemistry, immunofluorescence studies, protein-protein interaction studies, ELISA, and affinity purification.

[0089] Although derived from the endogenous protein β-netin, it has been surprisingly found that proteins fused with the label of the present invention are specifically and reliably detected using label-specific antibodies without significantly affecting any interaction between the antibody and the endogenous protein. Unbound by this theory, this is expected because endogenous β-netin is part of a protein complex that forms so-called adhesion linkages and is therefore not available for efficient interaction with label-specific antibodies. Furthermore, it has been found that BC2-Nb has an increased affinity for the epitope label (1.4 nM) compared to the affinity (3.7 nM) of the label-specific antibody BC2-Nb for endogenous β-netin, indicating that antibody binding to the labeled peptide is superior to antibody binding to endogenous β-netin.

[0090] Label-specific antibodies can be used to specifically and reliably detect peptides, such as peptides or proteins of interest, that have been fused with or linked to the epitope markers of this invention, for example, as described in detail below. Labeled peptides can also be specifically, efficiently, and reliably purified using immunoaffinity-based capture assays.

[0091] A further aspect of the invention is a construct consisting of a polypeptide and at least one epitope peptide as described above at the N-terminus or C-terminus of the polypeptide. The term "construct consisting of a polypeptide and at least one epitope peptide" refers to a non-naturally occurring polypeptide, which may also be referred to as a "fusion protein." The polypeptide included in the construct may include at least the protein of interest and optionally a linker sequence; it may also include further functional sequences and / or further markers. The construct may have one or more epitope markers of the invention. If the construct includes more than one marker, those may be arranged in tandem, may be continuous, may be spaced apart, or may be located at opposite ends. Furthermore, the construct may include further markers, which may be located at any useful location.

[0092] A further aspect of the invention relates to nucleic acids encoding the epitope peptides of the invention. The nucleic acid may be RNA, DNA, PNA, or LNA.

[0093] The nucleic acid constructs of the present invention comprise a nucleic acid sequence encoding at least one epitope peptide of the present invention. These nucleic acid constructs may have a prokaryotic or eukaryotic origin, such as bacteria, mammals, yeast, fungi, nematodes, fish, birds, viruses, or insects. Optionally, the nucleic acid constructs of the present invention also comprise a nucleic acid sequence of a polypeptide to be labeled, such as a protein of interest. The nucleic acid sequence encoding the epitope peptide of the present invention may produce a C-terminal and / or N-terminal labeled polypeptide downstream and / or upstream of the nucleic acid sequence encoding the polypeptide to be labeled. It has been surprisingly found that the epitope peptide of the present invention can be used at both the C-terminus and the N-terminus. This allows for very versatile uses of the epitope peptide or the nucleic acid encoding it, respectively. The constructs of the present invention may comprise a nucleic acid encoding one epitope peptide or multiple copies of the epitope peptide, such as two or three copies. More than one copy may be labeled adjacent to the end or the label may be located at the N- and C-terminus, respectively.

[0094] The constructs of this invention can also be nucleic acid expression constructs, comprising at least one nucleic acid encoding an epitope marker and at least one nucleic acid encoding a polypeptide to be labeled, wherein the two can be directly located adjacent to each other or separated by a linker sequence of a suitable length, such as about 3-150 nucleotides. Other functional sequences may also be included. For example, the linker may include a nucleic acid sequence encoding a recognition site for a nuclease or a recognition site for a protease. Examples of proteases are TEV protease, thrombin, factor Xa protease, or PreScission protease.

[0095] The nucleic acid constructs or nucleic acid expression constructs of the present invention may further include nucleic acid sequences that encode further markers, such as HIS-markers.

[0096] The nucleic acid constructs or nucleic acid expression constructs of the present invention may include nucleic acid sequences encoding more than one type of marker, such as tandem markers. A tandem marker is a sequential combination of two markers. A tandem marker may include at least two copies of the epitope markers of the present invention, or at least one epitope marker of the present invention and at least one other marker. The construct may also include a large number of identical or different markers, if appropriate.

[0097] A further aspect of the invention relates to host cells comprising the nucleic acids or nucleic acid expression constructs of the invention. A “host cell” is a cell comprising a nucleic acid sequence encoding an epitope marker of the invention. The host cell may be a stable transfectant or a nucleic acid construct thereof that can be transiently transfected with a nucleic acid sequence comprising an epitope marker.

[0098] The host cell can be a prokaryotic or eukaryotic cell. For example, the host cell can be a bacterial, yeast, insect, mammalian, plant, fungal, nematode, fish, or bird cell. The cell can be a primary cell or a cell line. The host cell can be a single cell or a cell that is part of a tissue.

[0099] A further aspect of the invention relates to a method for introducing the nucleic acid or nucleic acid expression construct of the invention into a host cell. The introduction results in the ligation of a nucleic acid encoding at least one epitope marker of the invention into a nucleic acid in the host cell encoding at least one polypeptide of interest. Thus, the host cell includes a nucleic acid encoding at least one epitope marker of the invention and will include the epitope marker of the invention after expression.

[0100] The method used to introduce nucleic acids into the host can be any method known in the art for this purpose. Specifically, the method can be selected from CRISPR / Cas genome editing, genome editing methods using zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), or a wide range of nucleases, reagent-based methods using reagents such as anionic lipids, calcium phosphate, or DADE-glucan, transduction, transfection, and instrument-based methods such as electroporation, microinjection, and laser transfection.

[0101] A further aspect of the invention relates to the use of the epitope peptides of the invention as N-terminal or C-terminal epitope markers. Host cells comprising nucleic acids encoding the epitope markers of the invention will express polypeptides, such as the polypeptide / protein of interest, which are linked to or fused to the epitope marker. Depending on the sequence of the nucleic acid expression construct and / or the method of introducing the nucleic acid encoding the epitope marker, the introduction of the host will result in an N-terminal or C-terminal labeled polypeptide. C-terminal or N-terminal markers are preferred compared to internal markers because the terminal markers will be more readily accessible for interaction with marker-specific antibodies. However, the epitope peptides of the invention can also be used as internal markers, provided that the protein of interest exhibits a conformation in which the internal marker is accessible for interaction with a binding partner. For example, the protein of interest may exhibit a loop structure, wherein the internal marker is part of the sequence forming the loop structure. In this case, the internal marker will be accessible for interaction with a binding partner.

[0102] According to this application, the term "affinity ligand" refers to a molecule that can bind with very high affinity to a specific portion thereof or to an antibody produced against it. Examples include biotin (ligand)-streptavidin (partial), digoxigenin (ligand)-anti-DIG-antibody, and further labeled specific antibodies. "Antibody" according to the invention includes monoclonal antibodies, polyclonal antibodies (specifically polyclonal monospecific antibodies (i.e., antibodies with different variable regions, yet all recognizing the specific epitope markers of the invention)), chimeric antibodies, and fragments or variants of antibodies of the types listed above. The term "antibody" as used herein also includes genetically manipulated antibodies, and in a preferred embodiment, the term "antibody" refers to heavy chain antibodies, such as those found in camels or llamas. The binding element of these antibodies consists of a single polypeptide domain, namely the variable region (VHH) of the heavy chain polypeptide. These antibodies naturally lack the light chain, where the heavy chain variable domain forms a complete antigen-binding site. In contrast, conventional antibodies have binding elements comprising two polypeptide domains (variable regions of the heavy chain (VH) and the light chain (VL)). In terms of ease of production and properties in solution, the independence from interactions with light chain variable domains to maintain structural and functional integrity gives these VHH domains numerous advantages over other small molecule fragments. Specifically, VHH fragments are a preferred type of molecule for immunoaffinity purification due to their unusual stability and their efficient refolding ability after complete denaturation, which frequently occurs during antigen elution. VHH antibodies are also known as single-domain antibodies or single-chain antibodies. Fragments of VHH antibodies are also referred to as “nanobodies.” Antibody fragments are well known in the art, and any fragment with epitope-binding activity can be used as an “antibody” in the system or for the interactions of this invention.

[0103] In the context of this invention, the term "antibody" generally refers to full-length antibodies and antibody fragments of the antibodies mentioned above, as well as variants defined below. Antibodies that do not contain all domains or regions of a full-length antibody are antibody fragments in the context of this invention. Thus, the term "antibody" should encompass any type of antibody, its fragments and variants, and mixtures of antibodies, fragments, and / or variants.

[0104] Any antibody can be used that has affinity for and is specific to the epitope peptide of the present invention and provides high antibody affinity or antigenicity. It can be a conventional antibody or a heavy chain antibody, or a fragment of a conventional antibody or a camelid antibody, or a mixture of antibodies, fragments, and / or variants. Preferred antibodies or antibody fragments are derived from heavy chain antibodies, such as camelid antibodies, and camelid antibody fragments, which are referred to as nanobodies or Nb.

[0105] All antibodies mentioned above may exist in bound or soluble form and may include detectable portions, or "tags" (e.g., fluorescent labels, radioisotopes, colloidal gold labels, coupled enzymes, etc.), and / or may carry peptides, groups, or linkers for immobilization on a solid phase. The term "bound" refers to both membrane-bound antibodies and antibodies immobilized to a solid support or carrier material. In the context of antibodies, the term "soluble" refers to antibodies that do not bind to a membrane or solid support, as is readily understood by those skilled in the art.

[0106] A further embodiment of the invention is a construct comprising a polypeptide and at least one epitope peptide, as defined above and in the claims, located at its N-terminus or C-terminus. The polypeptide may be any polypeptide as outlined above and may, for example, include at least the protein of interest and optionally further functional sequences, such as further markers. The construct may include one or more epitope markers, as described above.

[0107] This construct or labeled peptide can be captured and / or detected by measuring the interaction between the labeled peptide and a label-specific affinity ligand—such as a label-specific antibody, which may include a detectable portion and / or be able to bind to or bind to a solid support. The construct or labeled peptide of interest can be captured using a label-specific affinity ligand, such as a label-specific antibody, for purification or enrichment, and the labeled peptide can optionally then be detected and / or quantified by known means, such as a second detection ligand, which preferably includes a detectable portion, such as a fluorescent tag, and interacts with the peptide of interest, or optionally, with a label-specific affinity ligand, such as a label-specific antibody.

[0108] For detection, the labeled peptide and / or labeled specific affinity ligands, such as specific antibodies, may include a detectable portion or a portion that allows the introduction of the detectable portion or generates some kind of signal. Detectable portions and methods for detecting and / or quantifying the portion / signal are well known in the art. It is also possible to enrich the peptide of interest and subsequently analyze the binding coupler, amount, and other properties of interest of the labeled peptide.

[0109] Therefore, in a preferred embodiment, the present invention relates to methods for detecting and / or capturing, such as methods for purifying peptides by capturing, and / or methods for detecting peptides by capturing and / or measuring detectable signals, or by enriching the peptide in a obtained composition and analyzing the peptide.

[0110] The detection method of the present invention is suitable for determining the presence, subcellular localization, and / or amount of the epitope peptide or epitope-labeled polypeptide of the present invention, and is preferably an in vitro method.

[0111] The labeled peptide or protein to be detected, located, and / or quantified can be detected at its intracellular location within the host cell, such as in the nucleus, the cell membrane, or another cellular compartment. The labeled peptide or protein to be detected and / or quantified can also be detected in a solution containing the labeled peptide or protein, for example, in cell lysates obtained from host cells or tissues containing host cells.

[0112] In the first step of the detection method, an affinity ligand, such as an antibody that specifically binds to the epitope peptide of the present invention, is applied to a sample comprising a labeled polypeptide or protein. This sample may be a host cell, tissue, a solution containing cell lysate of the host cell, or any other sample comprising the labeled polypeptide, such as a supernatant, obtained after centrifugation of a liquid containing host cells, wherein the host cells are capable of secreting the polypeptide of interest into the liquid or another sample, such as bodily fluids.

[0113] This application step is performed under conditions that allow for specific interactions between affinity ligands, such as antibodies, and their epitope markers. Such conditions are well known to those skilled in the art. A washing step is typically performed after the antibody has been applied to its antigen, and those skilled in the art know how and when to apply this washing step.

[0114] In one embodiment, the interaction between an affinity ligand, such as an antibody, and its epitope label is detected, quantified, and / or localized to the labeled peptide or protein. Detection can be performed as is known in the art. In one embodiment, at least one of the two interacting partners, typically an epitope label-specific affinity ligand, such as an antibody, includes a detectable portion.

[0115] After being applied to a sample, such as host cells or a solution or cell supernatant containing cell lysates, an affinity ligand, such as an antibody, will specifically interact with the labeled protein. This interaction can be detected, monitored, and quantified by measuring or observing a reporter molecule signal obtained from the detectable portion. For example, if the detectable portion is a fluorescent tag, fluorescence can be detected and observed after excitation.

[0116] In another embodiment, the detection method is implemented by using the following method:

[0117] Epitope-specific affinity ligands, such as antibodies, do not need to include a detectable portion in this embodiment;

[0118] At least one second binding partner may bind to an epitope-specific affinity ligand such as an antibody, a labeled protein, or a complex constructed from both. The second binding partner may include a detectable portion and / or may be immobilizable.

[0119] In the first step, an epitope-specific affinity ligand, such as an antibody, is applied to a sample, such as a host cell or a solution containing host cell lysate, as disclosed above. In the second step, a second binding partner may be applied to a sample, such as a host cell or a solution containing host cell lysate, comprising a labeled polypeptide or protein bound to an epitope-specific affinity ligand, such as an antibody.

[0120] The presence, amount, and / or location of a labeled polypeptide or protein can be detected or determined by measuring or observing the reported molecular signals obtained from the detectable portion included in the second binding partner.

[0121] The advantage of a two-step detection method using two types of binding couples lies in the separation of label-specific interactions from the actual detection step. This allows the label-specific affinity ligand, such as an antibody, to remain unchanged because it does not need to include the detectable portion. This can enhance the specificity or affinity of the label-specific affinity ligand, such as an antibody, compared to a label-specific affinity ligand, such as an antibody, that includes the detectable portion, as the detectable portion may affect the interaction between the label and its affinity ligand, such as its antibody. Consequently, the reliability and efficiency of the detection method can also be enhanced. Furthermore, using a label-specific affinity ligand, such as an antibody, simply as a capture affinity ligand, such as a capture antibody, and not as a capture and detection affinity antibody, such as a capture and detection antibody, allows for the separation of the capture and detection steps if only the presence and amount of the labeled protein or peptide are to be determined. Therefore, the first step using a label-specific affinity ligand, such as a label-specific antibody, can be performed after an isolation or enrichment step to obtain the captured labeled protein or peptide of interest. The isolation or purification step will be discussed further below in this application. The detection step can then be performed on the isolated and / or enriched labeled protein, resulting in enhanced reliability and easier operation of the detection step for the obtained quantification.

[0122] Suitable biophysical or biomolecular detection methods for qualitative detection of epitope marker / antibody interactions include any suitable methods known in the art. Such methods are not limited to those used for qualitative or quantitative analytical applications, such as enzyme-linked immunosorbent assays (ELISA), ELISPOT assays, Western blotting, or immunoassays. Such methods include, for example, optical, radiometric, or chromatographic methods, preferably fluorescent or radiometric detection methods when using any of the above-mentioned tags, markers, or linkers.

[0123] Coomassie blue staining, silver staining or other protein staining methods, electron microscopy methods, and methods for staining tissue sections by immunohistochemistry or by direct or indirect immunofluorescence staining, etc. Such methods may use antibody application or may include the use of further tools, such as the use of a second binding partner, specifically binding to a portion of a labeled polypeptide, antibody, or complex.

[0124] Depending on the size of the antibody used, subcellular localization of the labeled peptide or protein of interest can also be determined. For example, if the detection antibody is small enough, different subcellular structures, such as intermediate filamentous networks or essential parts of the replication machinery, can be visualized and monitored.

[0125] In this aspect of the invention, the detection antibody is preferably a nanobody because nanobodies can interact with proteins located at subcellular sites, such as structures deeply embedded in chromatin, due to their reduced size compared to conventional antibodies. Because of the absence of variable light chains, nanobodies possess only three hypervariable loops (complementarity-determining regions, CDRs) compared to the six CDRs present in conventional antibodies. The three CDRs are flanked by four framework regions (FRs). To compensate for the loss of CDRs, Nb exhibits distinctive characteristics in their CDR structure and antigen-binding mode. To provide... With a sufficiently large antigen-interaction surface[1], most nanobodies exhibit significantly elongated CDR3 rings[2]. In some cases, the increased flexibility of these long rings is offset by binding them to the Nb core using additional disulfide bonds[3].

[0126] A typical nanobody can therefore be schematically represented as an amino acid sequence including the following regions:

[0127] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

[0128] A particularly preferred antibody is the BC2 nanobody (BC2-Nb), which exhibits excellent properties such as very high affinity, strong binding, and versatility. BC2-Nb comprises the variable region of a camel family heavy chain antibody, consisting of frame region 1, CDR1, frame region 2, CDR2, frame region 3, CDR3, and frame region 4, as defined by the following amino acid sequence (122aa):

[0129] QVQLVESGGGLVQPGGSLTLSCTASGFTLDHYDIGWFRQAPGKEREGVSCINNSDDDTYYADSVKGRFTIFMDNAKDTVYLQMNSLKPEDTAIYYCAEARGCKRGRYEYDFWGQGTQVTVSS (SEQ ID NO: 6; boldface indicates CDR)

[0130] Table 1: Regions that define the amino acid sequence of BC2-Nb:

[0131]

[0132]

[0133] It has been found that CDR3 is primarily responsible for the strong binding of the epitope peptide of the present invention. Another important part of the amino acid sequence of BC2-Nb is the cysteine ​​residue present in FR2 (at position 50 of SEQ ID NO:6). This cysteine ​​forms a disulfide bridge with the cysteine ​​residue of CDR3 and is therefore responsible for the proper folding of CDR3. Therefore, any nanobody is suitable as a partner for the epitope marker / nanobody interaction, which includes the CDR3 sequence of BC2 as CDR3 and includes a cysteine ​​residue in frame region 2, which is capable of forming a disulfide bridge with the cysteine ​​residue of CDR3. In a preferred embodiment, there are approximately 45 to 55, for example, approximately 50 or 51 amino acid residues between the cysteine ​​residue in FR2 and the cysteine ​​residue in CDR3. In the case of BC2-Nb, the cysteine ​​residue of FR2 is at position 50, and the cysteine ​​residue of CD3 is at position 102 (position markers indicate the positions as shown in SEQ ID NO:6 above). Therefore, there are 51 amino acid residues located between the cysteine ​​in frame region 2 and the cysteine ​​in CDR3.

[0134] Nanobody BC2-Nb, or functional variants thereof comprising at least cysteine ​​residues in CDR3 and FR2 of BC2-Nb, is also a preferred interacting partner for the epitope markers of the present invention in all disclosed purification and / or detection methods and / or uses disclosed herein, as it has been shown to be a very reliable and efficient binding partner for peptides containing the epitope markers of interest. BC2-Nb and its functional variants are also preferred components of the kits disclosed herein. A preferred embodiment of the invention is also the use of BC2-Nb or its functional variants for the detection, quantification, determination of subcellular localization of peptides containing the epitope markers of the present invention, or purification of peptides containing the epitope markers of the present invention.

[0135] Functional variants of BC2-Nb are any antibodies or fragments having an affinity for the epitope marker of the present invention, such affinity being at least 80%, more preferably at least 90%, or at least 95%, or even 99% or more, compared to BC2-Nb. The affinity between the variants and BC2-Nb can be measured as known in the art, and the results can be compared as known to those skilled in the art and by well-known analyses, such as by surface plasmon resonance (SPR) or by other protein-protein interaction monitoring analyses.

[0136] In a preferred embodiment, the present invention relates to a purification method, or a capture and purification method. The purification method can be used for analytical, semi-preparative, and preparative methods.

[0137] Therefore, a further aspect of the present invention relates to a method for purifying polypeptides, such as proteins of interest comprising at least one epitope marker of the present invention.

[0138] In this regard, the method includes a capture step of contacting a sample, such as a solution, containing a labeled polypeptide with an affinity ligand, such as an antibody, capable of specifically binding to the epitope label of the present invention. The affinity ligand specifically binding to the epitope peptide of the present invention is preferably an antibody, and most preferably a nanobody BC2-Nb or a variant thereof as defined above.

[0139] The sample to be contacted with the labeled specific antibody can be any type of sample including the labeled peptide and can be processed to isolate the peptide. Preferably, the sample is a solution, such as the lysate of host cells or body fluids including the labeled peptide, or a supernatant, such as a supernatant obtained by centrifuging a liquid containing host cells containing the construct or labeled peptide, wherein the host cells are capable of secreting or otherwise transporting the labeled peptide into the liquid.

[0140] In the methods of this invention, antibodies, fragments, or variants used to purify polypeptides, such as proteins of interest, can be used in solution or immobilized. To immobilize affinity ligands such as antibodies, fragments, or variants thereof targeting the epitope markers of this invention, the affinity ligands, such as antibodies, fragments, or variants, or mixtures thereof, can be bound to a sample carrier, solid support, or matrix. This immobilization step can occur before or after binding the affinity ligand, such as an antibody, to the epitope marker. Methods for immobilizing affinity ligands, such as antibodies, and portions thereof are well known to those skilled in the art, and any method that allows immobilization without impairing binding properties can be used.

[0141] If the affinity ligand, such as an antibody, that can specifically bind to the epitope peptide of the present invention is not immobilized to a solid support, the method may optionally include further steps for separating the complex, for example by using a binding partner of the complex, such as a second antibody, which is specific to, for example, the complex or (in the case of an IgG antibody) a constant portion of the antibody. The second binding partner may be in solution or may be immobilized or may be immobilized to a solid support.

[0142] In the context of this invention, the terms "solid support" or "matrix" should refer to any type of carrier material that can be used to immobilize affinity ligands such as antibodies or portions thereof, and can refer to materials in particulate (e.g., beads or particles, commonly used in extraction columns) or sheet form (e.g., membranes or filters, glass or plastic slides, microtiter plates, dipsticks, capillary-filled devices, etc.), which can be flat, pleated, or hollow fibers or tubes. Suitable and well-known matrices are not exhaustively limited to silica (porous amorphous silica), agarose, or polyacrylamide supports or macroporous polymers. Examples include dextran, collagen, polystyrene, polypropylene, polyvinyl chloride, polyacrylamide, methacrylates, cellulose, calcium alginate, controllable porous glass, aluminum, titanium and porous ceramics, synthetic polymers and copolymers, latex, silica, agarose, metals, glass, and carbon. Optionally, the solid surface may include a portion of a mass-dependent sensor, such as a surface plasmon resonance detector. Conveniently, an array comprising multiple individual affinity ligands, such as antibodies or antibody fragments, capable of specifically binding to the epitope markers of the present invention that have been bound to or immobilized to a solid surface is provided. Once the solution is contacted with the immobilized affinity ligands, such as antibodies or antibody fragments, this array can be used to capture the labeled peptides included in the solution.

[0143] In a further step following the capture step, the solid support containing the immobilized label-specific affinity ligand bound to the labeled peptide is optionally washed to remove unbound and non-specifically bound components. This can be used as a complex of ligand and peptide immobilization.

[0144] Optionally, in a further step, the labeled peptide can be eluted to obtain an isolated peptide, such as the protein of interest. Elution of the labeled protein bound to the immobilized antibody can be achieved by methods known in the art. For example, the labeled protein can be eluted by competitive elution with the isolated epitope peptide of the present invention. This isolated epitope peptide then competes with the labeled peptide for binding to the immobilized, label-specific antibody. If the isolated peptide is added in excess, the binding reaction equilibrium will shift to the binding of the immobilized antibody to the isolated epitope label. This results in the release of the labeled peptide. Additional steps, such as those well known to those skilled in the art, can then optionally be added for further purification of the released peptide.

[0145] The labeled peptides can also be immobilized on a solid support, such as beads, and further processed in downstream applications such as mass spectrometry without an elution step.

[0146] In another preferred embodiment, the labeled protein, such as a labeled polypeptide comprising a linker with a cleavage site, can be cleaved using a suitable method, such as a protease, to remove the label, thereby releasing the polypeptide by the immobilized antibody, and the polypeptide can be obtained in its natural form. For this embodiment, the nucleic acid sequence encoding the polypeptide should include not only the sequence encoding the epitope label but also the sequence encoding a linker with a cleavable site, such as a cleavage site recognized by a protease. The release step via enzymatic cleavage can replace the elution step or be performed after the elution step.

[0147] The present invention also includes a kit that includes components necessary for carrying out the methods of the present invention.

[0148] In one embodiment, a kit for capturing and / or detecting labeled peptides is provided.

[0149] The kit of the present invention, suitable for implementing the capture and / or detection method of the present invention, comprises the following components:

[0150] - A nucleic acid or nucleic acid expression construct encoding the epitope peptide of the present invention;

[0151] - Affinity ligands, such as antibodies, can specifically bind to the epitope peptides of the present invention;

[0152] - Optional detectable portions; and

[0153] - Buffer solutions and reagents, which are necessary for the capture and / or detection methods of the present invention.

[0154] Nucleic acid or nucleic acid expression construct encoding the epitope peptide of the present invention is introduced into host cells, as described above and as known to those skilled in the art. In this regard, the kit may also include buffers and reagents, which are essential for introducing the nucleic acid or nucleic acid expression construct encoding the epitope peptide of the present invention into host cells.

[0155] The affinity ligands that can specifically bind to the epitope peptides of the present invention are preferably antibodies, and most preferably nanobodies BC2-Nb or variants thereof, as defined above.

[0156] Affinity ligands, such as antibodies, capable of specifically binding to the epitope peptides of the present invention may include at least one detectable portion. The kit may also include at least one second binding partner that may bind to a unit provided on a complex or component thereof, such as avidin or streptavidin. If one of the complex or components thereof is biotinylated, or if the second and third antibodies for capturing the complex are constructed from labeled peptides and affinity ligands, such as antibodies, these further antibodies are, for example, specific to other portions of the peptide or epitope-specific affinity ligands, such as antibodies, or specific to a unit provided on the peptide, affinity ligand, such as antibody, or complex, such as a constant portion of a primary affinity ligand or antibody capable of specifically binding to the epitope peptide of the present invention. Further antibodies may also include detectable portions.

[0157] As defined herein, affinity ligands such as antibodies are particularly useful for detecting, capturing, and / or purifying polypeptides comprising the epitope peptides of the present invention. Therefore, one aspect of the present invention is the use of epitope-specific affinity ligands such as antibodies as defined herein, and more specifically, nanobodies, for detecting, capturing, and / or purifying polypeptides comprising the epitope peptides of the present invention.

[0158] The kit may further include a solid support comprising an affinity ligand, such as an antibody, that specifically binds to the epitope peptide of the present invention, wherein the epitope peptide of the present invention is immobilized or attached to the solid support.

[0159] The detectable portion can be any detectable portion as defined above. Preferably, the detectable portion is a fluorescent tag.

[0160] In a further embodiment, a kit for capturing and purifying labeled peptides is provided.

[0161] The kit for purifying labeled peptides includes the following components.

[0162] - A nucleic acid or nucleic acid expression construct encoding the epitope peptide of the present invention;

[0163] - Affinity ligands, such as antibodies, can specifically bind to the epitope peptides of the present invention;

[0164] -Optional solid support; and

[0165] - Buffer solutions and reagents, which are essential for the capture and purification methods of the present invention.

[0166] The nucleic acid or nucleic acid expression construct encoding the epitope peptide of the present invention will be introduced into host cells, as described above and as known to those skilled in the art. In this regard, the kit may also include buffers and reagents, which are essential for introducing the nucleic acid or nucleic acid expression construct encoding the epitope peptide of the present invention into host cells.

[0167] Affinity ligands, such as antibodies, that can specifically bind to the epitope peptides of the present invention are preferably nanobodies BC2-Nb or variants thereof as defined above.

[0168] Affinity ligands, such as antibodies, capable of specifically binding to the epitope peptides of the present invention can be in solution, immobilized, or attached to a solid support. The kit may also include further binding couplers as outlined above. Further binding couplers may also include a detectable portion.

[0169] The solid support can be any solid support as defined above, and the technician can choose a suitable method to immobilize or attach affinity ligands, such as antibodies, to the solid support.

[0170] The kit may also include reagents suitable for releasing captured labeled peptides from affinity ligands, such as antibodies, capable of specifically binding to the epitope peptides of the present invention. Thus, the kit may, for example, include the isolated epitope peptides of the present invention. It may also include enzymes capable of releasing captured labeled peptides from affinity ligands, such as antibodies, capable of specifically binding to the epitope peptides of the present invention by cleaving the peptide label. For example, the enzyme may be a protease such as TEV protease, thrombin, factor Xa protease, or PreScission protease. Example

[0171] The preferred embodiments of the present invention are outlined in the following examples, which should not be construed as limiting the scope or spirit of the invention.

[0172] Example 1: Overview

[0173] BC2 nanotraps are generated by covalently coupling monovalent BC2-Nb to a solid matrix. This acts as a highly efficient pull-down agent similar to the previously described GFP nanotraps[4], which are widely used to purify GFP-labeled complexes from cell lysates[5]. The excellent binding properties of BC2 nanotraps are advantageous for proteomics analysis, where they are used in binding reactions under conditions of high competition, such as using elution agents (up to 4 M urea or 1.5 M GdmCl) or denaturing washes (2% SDS)[6]. In contrast to GFP nanotraps, where bound proteins are released only under denaturing conditions, proteins bound by BC2 nanotraps can be eluted by peptide competition in functional conformation using only low amounts of BC2-peptides (0.1–1 mM). Localization cloning revealed that BC2-labels localized to either the N- or C-terminus were also well recognized by BC2 nanotraps. For N-terminal labeled GFP, additional bands were observed in the unbound fractions. This indicates that the BC2-marker may be removed by proteolytic hydrolysis after cell lysis, a phenomenon that has been described for other epitope markers in mammalian expression systems [7].

[0174] The BC2-based capture and detection system described in this study is an attractive alternative to currently available epitope labeling systems. The applicant of this invention has demonstrated BC2-Nb with a Kc of ~1.4 nM. D Proteins that bind to BC2-labeled epitopes and thus exhibit ~10-100 times higher affinity compared to available FLAG, HA, c-myc or nanobody-derived EPEA systems [8-10].

[0175] Recently, nanobodies targeting β-binin have been developed that recognize different epitopes within the amino acid sequence of β-binin. These antibodies have been used to monitor endogenous β-binin within cells

[11] . One of these Nb, known as BC2-Nb, recognizes a short linear epitope corresponding to aa 16-27 of β-binin.

[0176] Detailed structural and biochemical analyses of BC2-Nb and its interaction with a peptide epitope, hereinafter referred to as BC2-labeled (BC2T), are presented here. The data reveal an unusual binding mechanism mediated by the extended CDR3 and the framework of BC2-Nb, termed "head-lock binding." Based on the high-affinity binding properties of BC2-Nb, a novel BC2-labeled purification and detection system was developed and characterized. Immobilized BC2-Nb efficiently captures and purifies BC2-labeled proteins from bacterial and mammalian cell extracts in their native folded state. For the first time, detection of peptide-labeled cellular proteins using fluorescently labeled nanobodies was demonstrated through co-localization analysis. This versatile capture and detection system now enables a unique combination of biochemical and microscopic analyses of a wide variety of proteins, including these small, inert peptide-labeled proteins.

[0177] Generates with very high affinity (K D Nanobodies (~1.4 nM) binding short linear peptides. Structural analysis of the BC2-Nb / BC2-peptide complex revealed an unusual binding mode in which the BC2 peptide forms an additional antiparallel p-chain inserted into the β-sheet structure formed by CDR3 and the framework region. Numerous backbone hydrogen bonds provide affinity, and the salt bridge between Arg106 of CDR3 and Glu44 of FR2 surrounds the bound peptide in a headlock-like manner. Comparison with all nanobody complexes available in the Protein Database (PDB) showed that this binding mode had not been previously observed in any of the 81 known crystalline complexes. Affinity measurements of the headlock-mutated BC2-Nb showed a ~10-fold decrease in binding affinity and a higher dissociation rate. These data clearly indicate that the primary function of the headlock is to secure the already bound peptide to the nanobody.

[0178] Epitope analysis using position-scanning peptide libraries revealed a group of four specificity-determining residues, with W10 being the most critical. In contrast, other residues did not contribute to binding specificity, primarily because they are not involved in contact. The BC2T / BC2-Nb system is particularly versatile due to its reliance on numerous skeletal interactions to generate affinity and its specificity with only four amino acid side chains. Most of the BC2T residues can be substituted without sacrificing binding efficiency, and this allows for direct modification of the label for individual applications, including charge modification, the addition of tryptophan residues to increase absorbance at 280 nm, the introduction of protease cleavage sites, or even the introduction of unusual amino acids for labeling purposes.

[0179] Ultimately, the study shows that BC2-Nb offers new opportunities for cell imaging. Fundamentally, nanobodies can be readily modified with site-specific labeling using a full range of available organic dyes and used for direct imaging of cellular structures without the need for a secondary antibody for detection. Recently, it has been demonstrated that GFP- and RFP-specific antibodies labeled with photosensitive localization microscopy (PALM)-compatible organic dyes such as Alexa Fluor 647 (AF647) can efficiently visualize fluorescent fusion proteins in high-resolution microscopy. There remains a persistent need for nanobodies that recognize smaller epitopes to minimize steric hindrance or potential linking errors arising from large labels such as GFP- or RFP. In this study, for the first time, it has been demonstrated that fluorescently labeled peptide-specific nanobodies can be used to visualize diverse subcellular structures, such as intermediate filamentous networks or essential parts of replication machinery. Based on these findings, the inventors propose a BC2-mediated detection system that offers unique advantages compared to currently available approaches. First, due to its small size (12 aa, 1.4 kDa), BC2-labeling does not interfere with the subcellular localization or folding of ectopically expressed proteins. Second, the use of small nanobodies (2×4 nm) directly correlates the detection signal with the corresponding antigen. Third, BC2 nanobodies can be easily modified, for example, by site-specific labeling with suitable high-resolution compatible dyes. In summary, nanobody-mediated labeling of BC2-labeled constructs now combines minimal epitope labeling with the high photon yield and minimal linker error of organic dyes.

[0180] Example 2: Structural basis of epitope bonding

[0181] Since most of the described Nb have conformational epitopes, the underlying molecular mechanism of the observed high-affinity binding is resolved by analyzing individual BC2-Nb (in (at the resolution) and combined with BC2T The high-resolution crystal structure was used for investigation. From now on, BC2T amino acids will be referred to with a one-letter code and BC2-Nb amino acids with a three-letter code to facilitate the presentation and discussion of results. Amino acid position refers to the position of the amino acid residue in an epitope marker consisting of 12 amino acids (such as (PDRKAAVSHWQQ) defined in SEQ ID NO:4).

[0182] BC2-Nb adopts a typical immunoglobulin fold, consisting of nine β-chains forming two β-sheets linked by a loop and a conserved disulfide bond between Cys22 and Cys96. Figure 5a). Similar to other nanobody structures, BC2-Nb is characterized by an exceptionally long CDR3, which contains 14 amino acids and is stabilized by additional disulfide bonds formed between Cys102 (located in CDR3) and Cys50 (located in frame region 2 (FR2)). Figure 5 a). BC2T binds to the elongated conformation of BC2-Nb, inserting into the groove between FR2 and FR3 of CDR3 and BC2-Nb. The peptide is integrated into the BC2-Nb structure, forming a chain within the β-sheet. Figure 1 a). This results in a large number of skeletal hydrogen bonds that anchor the peptide to adjacent second structural elements. Notably, neither CDR1 nor CDR2 participates in the interaction with BC2T. Figure 1 a) See Table 2 below.

[0183] Table 2

[0184]

[0185] Unbound and bound BC2-Nb structures are similar and can be superimposed with small global root mean square deviations (RMSD) of atomic positions. (Phenix structure comparison). The CDR3 ring specifically has a similar orientation, except for two amino acids (Arg106 and Tyr107) that are flipped almost 180 degrees. Figure 5 b). In the uncoordinated BC2-Nb, the β-carbon of Arg106 is oriented towards the core structure of Nb, while the Arg106 side chain interacts with the skeletal carbonyl group of Glu108 and the π-electron system with Tyr109. The β-carbon of Tyr107 is oriented away from Nb, and the aromatic ring participates in the cation-π interaction with Arg45. In the complex, residues Arg106 and Tyr107 are flipped because their β-carbons and their side chains face opposite directions. Arg106 now participates in a charge-mediated interaction with the side chain of Glu44 located in FR2 ( Figure 1 b). This unusual interaction—which the inventors call a “headlock”—goes over the bound peptide and locks it securely in place. Several direct and water-mediated interactions hold the peptide firmly attached to its binding site ( Figure 1 c). However, only a small subset of BC2T residues are involved in these contacts: R3 forms a salt bridge with Asp110, S8 participates in a hydrogen bond with the carbonyl group of Lys103 and also complexes with water molecules along with Tyr109, and W10 is buried in a hydrophobic pocket in which it forms both a CH-π interaction with Cys50 and a hydrogen bond with the carbonyl group of Cys102. Figure 6 (A complete overview of all interactions is shown).

[0186] The effect of point mutations on the binding properties of BC2-Nb was investigated. First, by replacing Cys50 with alanine and Cys102 with serine (BC2-Nb...). C50A_C102S Remove the additional disulfide bonds linking CDR3 and FR2. Use modified GFP—which contains BC2T as the C-terminal peptide marker (GFP). BC2T The binding study revealed that this mutation resulted in the complete loss of binding (data not shown). The most likely explanation for this result is that maintaining the structure of CDR3 requires a disulfide bridge, which contributes to most of the contact with BC2T. The contribution of the "headlock" motif to binding was then analyzed. Arg106 was replaced by serine (BC2-Nb). R106S ) or glutamate (BC2-Nb R106E ), and use GFP BC2T Surface plasmon resonance (SPR) measurements were performed on the constructs. Ka values ​​of ~11 nM were obtained for both mutant proteins. D The value, which is related to BC2-Nb(K) D The concentration of 1.4 nM is about 10 times lower (see Table 3 below). Figure 7 Interestingly, wt and the mutant proteins showed similar binding rates (on-rate), while significantly higher dissociation rates were observed in both mutants (Table 3). In summary, the modest alteration in affinity is consistent with the structural analysis. The thirteen skeletal interactions of the extended peptide clearly contribute to the high affinity of the interactions. The “headlock” most likely helps ensure binding of the peptide, as indicated by the lower dissociation rate of the wt protein.

[0187] Table 3

[0188] Nb <![CDATA[R max [RU]]]> <![CDATA[K D [nM]]]> <![CDATA[K on [M -1 s -1 ]]]> <![CDATA[K off [s -1 ]]]> <![CDATA[ x 2]]> BC2-Nb 170±0.34 1.4±0.06 <![CDATA[4.6±0.04×10 5 ]]> <![CDATA[6.4±0.27×10 -4 ]]> 3.5 <![CDATA[BC2-Nb R106E ]]> 160±0.48 12.0±0.15 <![CDATA[2.8±0.01×10 5 ]]> <![CDATA[3.4±0.04×10 -3 ]]> 3.8 <![CDATA[BC2-Nb R106S ]]> 160±0.43 9.7±0.13 <![CDATA[3.3±0.03×10 5 ]]> <![CDATA[3.2±0.03×10 -3 ]]> 3.1

[0189] Example 3: Detailed epitope analysis of peptide libraries using synthetic site scanning

[0190] While high-affinity binding and kinetics can be explained by observed structural features, the specificity of complex formation must be demonstrated elsewhere. Due to the involvement of only a subset of BC2T residues and the specificity of Nb, side-chain mediated contact, position-scanning peptide libraries were used to examine the contribution of these individual amino acids to binding. In total, 12 different BC2T libraries displaying all 20 proteomic amino acids at a single position in the peptide were used in immunoprecipitation experiments. Immobilized BC2-Nb, BC2-Nb... R106S or BC2-Nb R106EBefore and after immunoprecipitation, the BC2T library underwent liquid chromatography followed by mass spectrometry analysis. The composition of the unbound peptides and, correspondingly, the variable amino acid positions were mapped by determining the peptides retained in the unbound fraction after precipitation (Table 4, below). Specifically, precipitated peptides were identified by comparative analysis of peptides in the supernatant of BC2-Nb or its mutants and in the supernatant of a non-BC2T-related control Nb (GFP-specific Nb). Direct comparison with GFP-Nb makes it possible to determine the quantification of peptide capture without the need for labeled standards. Thus, if BC2-Nb does not capture peptides, then… Figure 2 The ratio given will be one or close to one. The more peptide is captured, the closer the value is to 0. Because these peptides are isobaric, it is impossible to distinguish between the isoleucine (I) and leucine (L) peptide forms. However, the two peptide forms containing I / L can be distinguished and thus two values ​​are given as results.

[0191] Analysis showed that the BC2T residues at positions 1, 2, 4, 5, 7, 9, 11, and 12 of SEQ ID NO:4 could be substituted without affecting the epitope binding properties (Table 4, below). These results are consistent with the structure, which shows that the side chains of all eight residues are back-opposed to Nb. However, analysis of the supernatant of the R3, A6, S8, and W10 BC2T libraries revealed minimal cross-reactivity between the nanobodies and other amino acids at these positions. Figure 2 (ad). Notably, the binding peptide (BC2T) from the R3BC2T library... R3X It contains residues with basic properties, namely K3 or H3, or residues including smaller side chains, namely T3 or V3. Figure 2 a) This observation is consistent with the crystal structure, as the salt bridge between R3 and Asp110 could also be formed by H3 or K3. BC2T A6X Analysis of the library revealed a preference of BC2-Nb for small amino acids at position 6, as cysteine, valine, threonine, and serine permutants were effectively pulled down from the library. Peptides containing glycine, leucine, or isoleucine at this position were pulled down in smaller amounts. Figure 2 b). These results are consistent with the crystal structure, where the A6 side chain points to the small hydrophobic pocket of BC2-Nb. The binding of larger amino acids (i.e., leucine and isoleucine) would require conformational rearrangement, and glycine would introduce additional flexibility. For BC2T... S8X Similar effects were observed in the library. Alanine, cysteine, threonine, and valine can replace S8 while capturing other residues to a lesser extent. Figure 2c). The hydroxyl group at S8 forms a hydrogen bond with the carbonyl group of Lys103 on the nanobody. Cysteine ​​and threonine can participate in slightly similar productive interactions, while at least valine can be accommodated. Tryptophan at position 10 appears to be an invariant specific-determining amino acid in our peptide scanning studies, as none of the W10 exchanges are captured by BC2-Nb. Figure 2 d). This is highly consistent with structural analysis, which shows that the W10 side chain is inserted into a deep hydrophobic pocket on the nanobody.

[0192] mutant BC2-Nb R106S and BC2-Nb R106E The epitope scan results were almost identical to those of BC2-Nb, with one notable exception: BC2T. A6X Library analysis revealed that, in contrast to BC2-Nb, the mutated Nb also exhibited a small amount of precipitation with the BC2T variant, which carries either lysine or arginine at position 6. Figure 2 d). This observation suggests that the Arg45 mutation for Ser or Glu, which forms the headlock, results in slightly lower peptide specificity. In summary, four sites in BC2T with restricted or no amino acid variability were identified. The results are consistent with the structure, which shows that the side chains of R3, S8, and W10 are directly involved in BC2-Nb interactions, while the exchange at A6 may be sterically unfavorable and potentially prevent headlock formation. In conclusion, this analysis confirms that the side chain interactions of a small subset help determine the specificity of BC2-Nb for the BC2T sequence.

[0193]

[0194]

[0195]

[0196] Example 4: Generation of a BC2T-based capture system

[0197] Based on the unusual ligand binding mode of BC2-Nb, the goal was to develop a BC2T-based affinity system. Purified BC2-Nb was covalently coupled to agarose beads, generating an affinity matrix termed "BC2 nanotraps." First, the ability of the BC2 nanotraps to directly precipitate BC2T-labeled proteins from crude lysate was tested. Therefore, BC2 nanotraps were used to cultivate C-terminal labeled GFP (GFP... BC2T Soluble protein fractions of *E. coli* (wtGFP) or wtGFP (control) were analyzed by SDS-PAGE followed by Coomassie blue staining and immunoblotting, identifying the input, unbound, and bound fractions. Figure 3 a). The obtained data show that BC2 nanotrap quantitatively precipitates GFP. BC2TThen, BC2T purification was performed in the presence of various non-denaturing detergents (NP-40, Triton X100, CHAPS, or Tween 20, 0.1–1% w / v) or increased salt concentrations (0–500 mM NaCl, 2–50 mM KCl, 2–20 mM MgCl2). These reagents appeared to have no effect on binding efficiency (data not shown). Additionally, antigen binding was tested under denaturing conditions by increasing the concentration of sodium dodecyl sulfate (SDS) or dissociative agent (GdmCl; urea) in the binding buffer. BC2 nanotraps were observed to efficiently precipitate their antigens in the presence of 2% SDS, 4 M urea, or up to 1.5 M GdmCl. Figure 3 b). This indicates that the BC2 nanotrap remains functionally active under harsh conditions.

[0198] While such stringent binding and elution conditions may be advantageous for obtaining highly pure proteins in some cases, most bound proteins may be denatured and fail to maintain their biological activity. Therefore, milder elution conditions are tested using MgCl2 (0.5M–4M), sodium thiocyanate (NaSCN, 1–3M), or pH-mediated release (acidic; pH 1–2.5, or alkaline; pH 10–12). Competitive elution with increased concentrations of BC2 peptide (PDRKAAVSHWQQ, 0.01–1 mM) has also been used to test the binding of GFP. BC2T Release. Culture using MgCl2 does not wash away GFP. BC2T (Data not shown), while treatment with high concentrations of NaSCN or acidic elution (pH 1.5) resulted in the release of 30%-40% of the bound proteins. Figure 3 (c, top figure). In contrast, alkaline elution using higher pH values ​​(pH 11 and 12) revealed a more efficient release of 40–80%. Notably, ~60% and ~80% of GFP were detected in the elution fractions after the addition of 0.1 mM and 1 mM BC2 peptide, respectively. BC2T At that time, competitive elution is highly efficient. Figure 3 c, Figure below). Furthermore, treatment with NaSCN or acidic pH significantly affected GFP fluorescence, while alkaline pH or peptide elution yielded fully fluorescent GFP. Figure 8 These results show that BC2 peptides can efficiently replace proteins bound to BC2 in their native folded state.

[0199] Further analysis was conducted on the one-step purification of recombinant proteins derived from human cells using the BC2-capture system. Specifically, the influence of the BC2-tagged terminal position on binding was investigated. For this purpose, unlabeled eGFP was used as a negative control in human embryonic kidney (HEK) 293T cells, expressing eGFP at the N-terminus (…). BC2TeGFP) or C-terminus (eGFP) BC2T The sample included BC2-labeled modified GFP. Two days post-transfection, soluble protein fractions were generated and subjected to immunoprecipitation using BC2 nanotraps. The input, unbound, and bound fractions were analyzed by SDS-PAGE followed by Coomassie blue staining and Western blotting. Figure 3 d). The results showed that both N- and C-terminal BC2-labeled GFP constructs precipitated efficiently via BC2 nanotraps, while GFP was not detected in the negative control. BC2T A slightly smaller GFP fragment appeared in the unbound fraction of eGFP. Since this band did not appear in the binding lane, it is hypothesized that its appearance was due to removal mediated by the N-terminal BC2-labeled protease during the cell lysis procedure.

[0200] Next, it was tested whether BC2 nanotrap could precipitate BC2-labeled cellular components of intermediate filaments or nuclear replication machinery. BC2T genetically fused to mCherry-Vimentin (mCherry-VIM) BC2T ) or eGFP-PCNA (eGFP-PCNA) BC2T Both constructs were expressed in HEK293T cells. As a control, the corresponding constructs without BC2-labeling were used. Soluble protein extracts were cultured using BC2 nanotraps, and the intact lysate (input), unbound, and bound fractions were analyzed by immunoblotting using anti-Vimentin or anti-PCNA antibodies. Results showed that BC2 nanotraps efficiently precipitated mCherry-VIM. BC2T and eGFP-PCNA BC2T Both showed no detectable signal in the fraction of unlabeled protein binding. Figure 9 a). The next question is whether BC2-Nb can also be detected in immunoblotting of BC2-labeled proteins. Therefore, fluorescently labeled BC2-Nb was developed by chemically conjugating purified nanobodies to the organic dye AlexaFluor488(BC2-Nb). AF488 This is generated and used to detect immunoblots that express eGFP-PCNA, eGFP-PCNA BC2T mCherry-VIM or mCherry-VIM BC2T The soluble protein fractions of the cells. Results showed BC2-Nb AF488 Highly specific to BC2-labeled proteins, while no unlabeled proteins were detected. Figure 9 b). Finally, inquire whether BC2-Nb also recognizes endogenous β-linkin in the presence of BC2-labeled proteins. Although using BC2-Nb AF488No β-nexin signal was detected in the Western blot. Figure 9 b), however, compared to overexpressed BC2-tagged proteins, smaller amounts of β-linkin were found in the binding fraction after precipitation using BC2 nanotraps. Figure 9 c).

[0201] In summary, the results demonstrate that the BC2T / BC2-Nb affinity system enables robust and convenient one-step purification of BC2-tagged recombinant proteins from various expression systems under both native (i.e., non-denaturing) and denaturing conditions. Combined with the functional combinations observed in immunoblotting assays, the system covers the capture and detection of a full range of BC2-tagged proteins for a wide range of biochemical analyses.

[0202] Example 5: Immunocytochemistry using fluorescently labeled BC2-Nb

[0203] Numerous nanobodies have been described for molecular imaging of disease-associated antigens localized on cell surfaces [12-14]. Very few studies have to date explored the use of nanobodies for cell imaging

[15] . Therefore, it was necessary to test whether fluorescently labeled BC2-Nb (conjugated to the organic dyes AlexaFluor488 or ATTO647 (BC2-NbAF488; BC2-NbATTO647)) was suitable for visualizing BC2-labeled cellular proteins. To generate the relevant cellular target structures, the previously described fusion constructs mCherry-VIMBC2T or GFP-PCNABC2T were expressed in human cells (…). Figure 4 a) Fluorescent constructs of vimentin were incorporated into the cellular intermediate filament network and vimentin filaments were visualized in the cytoplasm after transient cellular expression

[16] , while GFP-PCNA was found at the site of DNA replication and formed characteristic dotted structures in the nucleus during the S phase of the cell cycle

[17] . The characteristic pattern of the applied fusion protein allowed for colocalization studies using immunocytochemistry with dye-labeled BC2-Nb.

[0204] By using BC2-Nb AF488 Staining to express mCherry-VIM BC2T HeLa cells were observed to show up in the red channel. Figure 4 b, Figure 10 a) Strong co-localization of green nanobody signals along the cytoplasmic vimentin structure. Correspondingly, BC2-Nb ATTO647 This revealed the interaction between GFP-PCNA and the replication focus during S phase. BC2T Clear co-localization of GFP-PCNA BC2T and BC2-Nb ATTO647The signals from both were found exclusively in the nucleus, demonstrating the binding specificity of BC2-Nb. No nanobody signal was detected in cells expressing mCherry-VIM or GFP-PCNA constructs lacking the BC2-label. Figure 10 b). These data demonstrate that fluorescently labeled BC2-Nb specifically binds to ectopically expressed BC2T fusion protein and can therefore be used for direct antigen detection in immunocytochemistry.

[0205] Example 6: Analysis of the effects of various mutations or truncations within the BC2 marker on the binding efficiency of BC2-Nb in pull-down assays.

[0206] As outlined in Example 3, it was demonstrated that the BC2T residues at positions 1, 2, 4, 5, 7, 9, 11, and 12 of SEQ ID NO:4 can be substituted. This was demonstrated by using a peptide library scan showing the positions of all 20 proteomic amino acids at a single location within the peptide.

[0207] To investigate the effect of multiple amino acid swaps within BC2T on binding performance in more detail, a mutant form of BC2T was generated by simultaneously swapping six amino acid residues. Therefore, Asp(D) at position 2 was replaced with Val(V); Lys(K) at position 4 was replaced with Ser(S); Val(V) at position 7 was replaced with Leu(L); His(H) at position 9 was replaced with Gln(Q); Gln(Q) at position 11 was replaced with Ser(S); and Gln(Q) at position 12 was replaced with Ser(S). This altered a total of 50% of the amino acid residues initially identified as the BC2T sequence (SEQ ID NO:5). The resulting amino acid sequence was termed BC2Tmut. To test whether these simultaneous swaps affected the pull-down efficiency of proteins including the mutated BC2-marker (BC2mut), BC2Tmut was genetically fused into GFP (GFPBC2Tmut). For pull-down analysis, soluble protein fractions were obtained from *E. coli* cells cultured using BC2 nanotrap expressing wtGFP (control), C-terminal BC2-labeled GFP (GFPBC2T), or GFPBC2Tmut, and analyzed by SDS-PAGE followed by Coomassie staining and Western blotting of the input, unbound, and bound fractions (see [link to analysis]). Figure 11 The obtained data show that BC2 nanotrap quantitatively precipitates GFPBC2T and GFPBC2Tmut. This suggests that multiple crossovers of amino acid residues at the indicator site do not affect the interaction and binding ability of the mutated BC2T with the BC2 nanotrap.

[0208] Next, the influence of N- or C-terminal truncation of BC2T on its binding properties with BC2-Nb was analyzed. Therefore, two constructs were generated. In the first construct (designated BC2T-10), the last two Gln(Q) residues located at the C-terminus of BC2T were deleted, resulting in the sequence PDRKAAVSHW. For the second construct, the first two amino acid residues, Pro(P) and Asp(D), located at the N-terminus of BC2T (BC2T-8; RKAAVSHW), were also deleted. For binding studies, BC2T-10 and BC2T-8 were genetically fused into GFP (GFPBC2T-10; GFPBC2T-8). For pull-down analysis, soluble protein fractions were obtained from *E. coli* cells expressing wtGFP (control), C-terminal BC2-labeled GFP (GFPBC2T), GFPBC2T-10, or GFPBC2T-8, cultured using BC2 nanotrap, and analyzed by SDS-PAGE followed by immunoblotting with anti-GFP antibody to determine the input, unbound, and bound fractions (see [link to analysis]). Figure 12 The data obtained show that BC2 nanotrap precipitates GFPBC2T-10 and GFPBC2T-8 in a manner comparable to that of GFP labeled with the original BC2T (GFPBC2T). This demonstrates that the deletion of the two amino acid residues flanking BC2T at the N- or C-terminus does not affect the interaction and binding ability of the truncated BC2T with the BC2 nanotrap.

[0209] Example 7: Development of an improved BC2T variant

[0210] Using a rational design approach, we developed variants of BC2T, aiming to further improve the affinity of the BC2 marker for BC2-Nb. To this end, based on... Figure 1 The structural and biochemical data reported in Table 4, along with molecular modeling substitutions of the BC2T residues at positions 1, 4, 5, 11, and 12 of SEQ ID NO:4, are used.

[0211] Two variants of BC2T, designated pTag1 SEQ ID NO:33 and pTag2 SEQ ID NO:34, were designed and found to exhibit a higher affinity for BC2-Nb compared to the original BC2T sequence (Table 5). Figure 13 Using the biolayer interferometry method, the dissociation constant K for the interaction between BC2-Nb and pTag1 SEQ ID NO:33 and pTag2 SEQ ID NO:34 is... D The K values ​​were determined to be 0.7 nM and 1.9 nM, respectively. In contrast, for the original BC2T (SEQ ID NO:4), the K value for interaction with BC2-Nb was... DIt is 2.6 nM (as determined using the biolayer interferometry method). Specifically, the dissociation rate constant k for pTag1 SEQ ID NO:33 off With respect to the dissociation rate constant k of the original BC2T off The 7-fold slower rate (Table 5) explains the unusually high affinity of BC2-Nb for pTag1 SEQ ID NO:34.

[0212] The applications of these improved variants of BC2T in protein purification and immunoprecipitation have been validated. Figure 14 The protein mCherry was fused at the N-terminus or C-terminus to the BC2T variants pTag1 SEQ ID NO:33 and pTag2 SEQ ID NO:34 (and the original BC2T SEQ ID NO:4 for comparison) and cultured using BC2 nanotrap. Figure 14 a). Subsequently, the captured fusion protein was eluted with the corresponding peptide at a concentration of 100 μM. SDS-PAGE analysis was performed on fractions of input, unbound protein, eluted protein, and protein still bound to the BC2 nanotrap after elution. Figure 14 a) The improved BC2 tagging is shown to capture fusion proteins regardless of tag localization. Furthermore, the captured proteins are eluted using free peptides, i.e., under native, non-denaturing conditions. Therefore, the improved BC2T variant can be applied to one-step protein purification of proteins of interest fused with such a BC2T variant. Compared to the original BC2T, the higher affinity of the improved BC2T variant for BC2-NB results in more efficient capture of the tagged protein, with up to 100% protein binding. Figure 14 a).

[0213] BC2 nanotraps can be used to precipitate and fuse proteins of interest from a range of organisms to modified BC2T variants. For example... Figure 14 As shown in b, the N-terminal fusion of pTag1 SEQ ID NO:33 with the protein mCherry allows for the highly specific recovery of this fusion protein from lysate products of human cell line HEK293T, the moth-like insect cell line High5, and Saccharomyces cerevisiae using BC2 nanotraps. This experiment ( Figure 14 b) The applicability of using cell lines common in the art, such as the BC2 nanotrap, along with the use of the protein marker pTag1 SEQ ID NO:33 of the BC2T variant, for the purification and precipitation of proteins from recombinant expression-related systems.

[0214] Table 5: Binding kinetics of the two improved BC2T variants compared with wild-type BC2T.

[0215]

[0216] Table Description: Analysis of the combination of BC2-Nb with BC2T (SEQ ID NO:4) and its two modified variants (pTag1 SEQ ID NO:33 and pTag2 SEQ ID NO:34) using the biolayer interferometry method (see original data). Figure 13 The dissociation constant (K) of the 1:1 combined model is listed. D ), association (k on ) and dissociation (k off Rate constant and markers of fit quality (χ²) 2 R 2 The constants reported for the original BC2T differ from those listed in Table 1 because different methods were used to analyze the kinetics.

[0217] In summary, a rational design approach enables the development of improved BC2T variants characterized by the high affinity of BC2-Nb. These improved variants can be fused to the N-terminus or C-terminus of the protein of interest, allowing for the efficient purification of such fusion proteins from various organisms. Moreover, similar to the original BC2T, these improved BC2T tags can be eluted from the BC2 trap using native non-denaturing conditions.

[0218] Example 8: Materials and Methods

[0219] Expression plasmid

[0220] For C-terminal BC2-labeled GFP(GFP) BC2T The bacterial expression of pEGFP-C1 (Clontech) was performed using an oligonucleotide primer, GFP, via polymerase chain reaction (PCR). BC2T _for (5′-GCA CCA TGG ATG GTG AGCAAG GGC GAG G-3′; SEQ ID NO: 15) and GFP BC2T _rev(5'-GAC GTC GAC TTA CTG CTG CCA GTGACT AAC A-3′;SEQ ID NO:16) amplifies the encoding GFP BC2T The sequence was then cloned into the NcoI / SalI restriction site of pTRC2A (Life Technologies). For those with an N-terminal His6-marker (His6-GFP)... BC2T Expression of C-terminal BC2-labeled GFP was achieved by PCR using the oligonucleotide primer His6-GFP. BC2T_for (5′-CAG GGA TCC GAG TGAGCA AGG GC-3′; SEQ ID NO: 17) and His6-GFP BC2T _rev(5′-CAG GGT ACC TTA CTG CTG CCAGTG ACT AA-3′;SEQ ID NO:18) amplifies the encoding GFP. BC2T The sequence was cloned into the BamHI / KpnI restriction site of pRSET B (Invitrogen) with an N-terminal His6-labeled fragment.

[0221] To generate a GFP fusion construct including 50% modified BC2 markers, pEGFP-C1 (Clontech) was used as a template. The oligonucleotide primer GFP was used via polymerase chain reaction (PCR). BC2Tmut _for(5'- GGA TCC GAT GGT GAGCAA GGG CGA G-3'; SEQ ID NO:19) and GFP BC2Tmut _rev(5'- GGT ACC TTA GCT GCT CCA CTGGCT CAG CGC CGC GCT CCG GAC CGG CTT GTA CAG CTC GTC CAT GC-3'; SEQ ID NO:20) amplified to encode GFP BC2Tmut The sequence was used. The PCR fragment was cloned into the previously generated GFP. BC2T BamHI / KpnI restriction sites of the expression construct.

[0222] To generate a bacterial expression vector encoding GFP with an N-terminal His6-label and a shortened C-terminal form of BC2T (BC2T-10 or BC2T-8), GFP-encoding vectors were amplified by PCR using pEGFP-C1 (Clontech) as a template. BC2T-10 or GFP BC2T-8 The sequence. For PCR, use the following oligonucleotide primers: His6-GFP. BC2T-10 _for: (5′-ccccGGATCCGATGGTGAGCAAGGGCGAGG-3′; SEQ ID NO:21) and His6-GFP BC2T-10 _rev(5′-ccccGGTACCTTACCAATGTGACACCGCTGCTTTGCGGTCAGGCTTGTACAGCTCGTCCATGCC-3′; SEQ ID NO:22) or His6-GFP BC2T-8_for(5′-ccccGGATCCGATGGTGAGCAAGGGCGAGG-3′; SEQ ID NO:23) and His6-GFP BC2T-8 _rev(5′-ccccGGTACCTTACCAGTGGGAAACGGCTGCTTTACGCTTGTACAGCTCGTCCATG-3′; SEQ ID NO: 24).

[0223] For mammalian expression of C-terminal BC2-tagged GFP, pEGFP-C1 was used as a template. The oligonucleotide primer eGFP was used for PCR. BC2T _for (5′-AAG CTA GCG CTA CCG GTC GCC ACC ATG-3′; SEQ ID NO: 25) and eGFP BC2T _rev(5′-AAG GTA CCT TAT TGC TGC CAG TGA CTA ACA GCC GCT TTT CTG TCTGGC TTG TAC AGC TCG TC-3′;SEQ ID NO:26) amplifies mammalian eGFP. BC2T The sequence of the construct was obtained. The PCR fragment was cloned into the NheI / KpnI site of the pEGFP-C1 vector.

[0224] For N-terminal BC2-labeled GFP ( BC2T Mammalian expression of GFP was performed, and nucleotide sequences (MWG) encoding BC2-tags (5′-GCT AGC ATG CCC GAT CGT AAG GCT GCG GTC TCT CAT TGGCAA CAG AGA TCT-3′; SEQ ID NO:27) with NheI and BglII restriction sites were synthesized. The tags were then cloned into the NheI / BglII sites of pEGFP-N1 (Clontech). The resulting plasmids were digested with XhoI and NheI, blunted using Klenow (Roche) enzymes, and then ligated to obtain the desired construct.

[0225] For mCherry-Vimentin BC2T For mammalian expression, the mCherry-Vimentin construct

[18] was used as a template. The mCherry-Vimentin was expressed by PCR using oligonucleotide primers. BC2T_for(5′-AAA AGC TTA GGT GGAGGA GGT TCT TCC ACC AGG TCC GTG TC-3′;SEQ ID NO:28) and mCherry-Vimentin BC2T _rev(5′-AAG GTA CCC TAT TGC TGC CAG TGA CTA ACA GCC GCT TTT CTG TCT GGT TCA AGGTCA TCG TG-3′;SEQ ID NO:29) amplifies the protein encoding mCherry-Vimentin. BC2T The nucleotide sequence was obtained. The PCR fragment was cloned into the HindIII / KpnI site of the mCherry-Vimentin vector.

[0226] For GFP-PCNA BC2T In mammalian expression, GFP-PCNA

[17] was used as a template. The oligonucleotide primer GFP-PCNA was used for PCR. BC2T _for (5′-GTA TGG CTT CGT GGG GAT CCC CG-3′; SEQ ID NO:30) and GFP-PCNA BC2T _rev(5′-GGG GTC TAG ACT AAA GGT ACC CTA TTG CTG CCA GTG ACT AACAGC CGC TTT TCT GTC TGG AGA TCC TTC TTC ATC CTC-3′;SEQ ID NO:31) amplifies the encoding GFP-PCNA BC2T The sequence was obtained. The PCR fragment was cloned into the BamHI / XbaI restriction site of the GFP-PCNA vector.

[0227] To generate a bacterial expression vector encoding mCherry with an N-terminal His6-tag and a C-terminal BC2T or a variant thereof, sequences encoding BC2T (SEQ ID NO:4) and variants pTag1 SEQ ID NO:33 and pTag2 SEQ ID NO:34 were synthesized as oligonucleotides, annealed, and cloned into the BrsGI and HindIII restriction sites of the plasmid vector pRSET-B_mCherry (ThermoFisherScientific). For this purpose, the following oligonucleotides were used: mCherry_BC2T_fw(5'-GTA CAG TGG TCC GGA TCG CAA AGC GGC GGT GAG CCA TTG GCA GCA GTA AA-3'; SEQ ID NO:35) and mCherry_BC2T_rv(5'-AGC TTT TAC TGC TGC CAA TGG CTC ACC GCC GCT TTGCGA TCC GGA CCA CT-3'; SEQ ID NO:36); mCherry_SEQ33_fw(5'-GTA CAG TGG TCC GGATCG CGT GCG CGC GGT GAG CCA TTG GAG CAG CTA AA-3'; SEQ ID NO:37) and mCherry_SEQ33_rv(5'-AGC TTT TAG CTG CTC CAA TGG CTC ACC GCG CGC ACG CGA TCC GGA CCACT-3'; SEQ ID NO:36) NO: 38); mCherry_SEQ34_fw (5'-GTA CAGT GGT GCG GAT CGC GTG CGC GCGGTG AGC CAT TGG AGC AGC TAA A-3'; SEQ ID NO: 39) and mCherry_SEQ34_rv (5'-AGC TTTTAG CTG CTC CAA TGG CTC ACC GCG CGC ACG CGA TCC GCA CCA CT-3'; SEQ ID NO:40).

[0228] To generate a bacterial expression vector encoding mCherry with a C-terminal His6-tagged label and an N-terminal BC2T or a variant thereof, sequences encoding BC2T (SEQ ID NO:4) and variants pTag1 (SEQ ID NO:33) and pTag2 (SEQ ID NO:34) were synthesized as oligonucleotides, annealed, and cloned into the modified plasmid vector pRSET-B_mCherry (ThermoFisher Scientific) encoding a C-terminal His6-tagged label, specifically the variants NdeI and BamHI restriction sites. For this purpose, the following oligonucleotides were used: mCherry_BC2T_fw2(5'-TAT GCC GGA TCG CAA AGC GGC GGT GAG CCA TTG GCAGCA GGG CTC G-3'; SEQ ID NO:41) and mCherry_BC2T_rv2(5'-GAT CCG AGC CCT GCT GCCAAT GGC TCA CCG CCG CTT TGC GAT CCG GCA-3'; SEQ ID NO:42); mCherry_SEQ33_fw2(5'-TAT GCC GGA TCG CGT GCG CGC GGT GAG CCA TTG GAG CAG CGG CTC G-3'; SEQ ID NO:43) and mCherry_SEQ33_rv2(5'-GAT CCG AGC CGC TGC TCC AAT GGC TCA CCG CGC GCACGC GAT CCG GCA-3'; SEQ ID NO:42) NO:44); mCherry_SEQ34_fw2 (5'-TAT GGC GGA TCG CGT GCGCGC GGT GAG CCA TTG GAG CAG CGG CTC G-3'; SEQ ID NO:45) and mCherry_SEQ34_rv2 (5-GAT CCG AGC CGC TGC TCC AAT GGC TCA CCG CGC GCA CGC GAT CCG CCA-3'; SEQ ID NO:46).

[0229] Protein production and purification

[0230] The expression and purification of BC2 nanobodies were performed as previously described

[11] . The expression and purification of wtGFP or its modified forms were performed as previously described. The purity of all proteins was evaluated to be at least 95% based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Protein concentrations were determined by spectroscopic methods.

[0231] Complex formation

[0232] For complex formation, a 2 mg / mL BC2-Nb solution was mixed and incubated for 1 h at room temperature with a three-molar excess of peptide in 10 mM Tris / HCl pH 7.4, 100 mM NaCl buffer. The excess peptide was removed by size exclusion chromatography (Superdex 200 increase, GE Healthcare). The complex was further processed using a Phenomenex Kinetex (2.6 μm C18) device. The formation of the complex was confirmed by liquid chromatography-mass spectrometry on a Shimadzu LCMS 2020 column. The complex was concentrated to 13.7 mg / ml and used in crystallization experiments.

[0233] Crystallization

[0234] Uncoordinated BC2-Nb was crystallized using hanging drop vapor diffusion by mixing a 3.2 mg / ml protein solution with a crystallization buffer (0.1 M MES / imidazole pH 6.7, 12.5% ​​[v / v] 2-methyl-2,4-pentanediol (MPD), 7.5% [w / v] PEG 1000, 7.5% [w / v] PEG 3350, and a 3 mM alcohol mixture) at a 1:1 ratio at 20 °C. The BC2-Nb / BC2T complex was crystallized using hanging drop vapor-phase diffusion by mixing a 13.7 mg / ml composite solution with a crystallization buffer (0.1 M MES / imidazole pH 6.5, 12.5% ​​[v / v] 2-methyl-2,4-pentanediol (MPD), 12.5% ​​[w / v] PEG 1000, 12.5% ​​[w / v] PEG 3350, and a 4 mM amino acid mixture) at a 1:1 ratio at 20 °C. In both cases, the crystals were transferred to a crystallization solution containing 30% [v / v] MPD for cryoprotection and rapidly cooled in liquid nitrogen for 30 s after incubation. The beam wavelength was collected at different locations at Helmholtz-Zentrum Berlin (HZB) in BESSY II beamline MX 14.2, with one dataset from BC2-Nb and four datasets from the same crystal of BC2-Nb / BC2T complex.

[0235] X-ray data were reduced and merged using the XDS package in the case of the BC2-Nb / BC2T complex

[20] . In the case of a CHAINSAW [22,23] modified model containing only the core region nanobody (PDB ID: 2X1O), the initial phase of BC2-Nb data was obtained by molecular substitution using PHASER

[21] . The structure of the BC2-Nb / BC2T complex was then resolved using the uncoordinated BC2-Nb structure as a search model in the molecular substitution. Both structures were refined using PHENIX.refine

[24] , REFMAC5

[25] , and COOT

[26] . Both structures were validated using MOLPROBITY

[27] . Ramachandran plots show 100% (BC2-Nb), 98.1% (BC2-Nb / BC2T complex), and 100% in the allowable region in the favorable region.

[0236] Structural visualization and analysis

[0237] Using the Phenix structure, we compare the superposition of the implemented structures and the calculation of RMSD values. Images of the crystal structures were prepared using PyMol (http: / / www.pymol.org).

[0238] Mass spectrometry analysis of binding specificity was performed using a synthetic site scanning peptide library.

[0239] To investigate the binding specificity of BC2T and its derived mutants, peptide libraries were used at each amino acid position of the synthetic sequence PDRKAAVSHWQQ (SEQ ID NO:4) with acetyl and amide groups (Intavis) positioned at the N-terminus or C-terminus, respectively. Precipitation studies were performed by cultivating 60 pmol peptides from single-position libraries using 2 μl of BC2-Nb immobilized on agarose beads. The peptides were incubated for 1 h in 300 μl PBS / 0.01% CHAPS on a HulaMixer (Life Technologies). After centrifugation, 10 μl of the supernatant was analyzed in an LC-MS program. Peptides were isolated using a UltiMate 3000 RSLCnano system (Thermo Scientific) consisting of a C18 PepMap 100 μ-prep column (300 μm × 5 mm; particle size: 5 μm; pore size: ). -Thermo Scientific) and C18 analytical column (Acclaim Rapid Separation LC (RSLC) column: 150mm × 5mm; particle size: 2.2μm; pore size: Composition (Thermo Scientific). A step gradient was applied starting at 8% and terminated after 20 min with 30% elution buffer B (80% acetonitrile, 20% H2O, 0.1% formic acid). Peptides were analyzed using a FULL-MS strategy detected by a Q ExactivePlus mass spectrometer (Thermo Scientific). A maximum injection time of 100 ms was selected, with an AGC target of 3E6 set. Resolution was set to 70,000. The half-maximum signal region was referenced to control the precipitation pathway using GFP-specific nanobodies immobilized on agarose beads. All experiments were performed in triplicate.

[0240] Cell culture and transfection

[0241] HEK293T and HeLa cells were cultured in DMEM (high concentration glucose, pyruvate) supplemented with 10% FCS, 2 mM L-glutamine, and Pen Strep (both from Gibco, Life Technologies). Cells were cultured at 37°C in a humidified chamber with a 5% CO2 atmosphere and passaged using trypsin. To generate the DNA / PEI complex in P100 plates for transient transfection, 24 μg of DNA was mixed with 108 μl of polyethyleneimine (PEI, Sigma Aldrich) pre-diluted with 750 μl of Opti-MEM (Gibco, Life Technologies) and incubated at RT for 10 min. For transfection of cells in 96-well plates, 200 ng of DNA and 1.5 μl of PEI were used.

[0242] Soluble protein fractions generated from bacterial cells

[0243] GFP or GFP expression derived from 1L culture BC2T The precipitate of *E. coli* cells was homogenized for 90 min at 4 °C in 500 μl PBS containing 0.1 mg / ml lysozyme, 5 μg / ml Dnase I, 50 μg / ml PMSF, and 1× protease inhibitor mixture B (Serva), followed by sonication (10×10 sec pulses). After centrifugation (18,000×g, 4 °C for 10 min), the soluble protein fractions were transferred to new cuvettes and the protein concentration of each lysate was determined using Coomassie Plus according to the manufacturer's protocol (Thermo Fisher Scientific).

[0244] Surface Plasmon Resonance

[0245] BC2 nanobodies and their indicated mutants against GFP were analyzed using surface plasmon resonance spectroscopy on a Biacore 3000 instrument (GE-Healthcare). BC2T Affinity measurement of GFP. BC2T Covalently coupled to dextran fibers on the CM5 sensor chip (GE Healthcare), achieving a response level of 500 RU. One flow cell was activated and blocked in the absence of protein to measure background, while another loaded with unlabeled GFP served as a control for nonspecific binding. For kinetic measurements, six concentrations of BC2-Nb ranging from 7.8125 nM to 250 nM were injected. R106S or BC2-Nb R106E Each measurement was performed in duplicate. The run / dilution buffer consisted of 10 mM HEPES pH 7.4, 150 mM NaCl, and 0.5% surfactant Tween. Measurements were performed at 25 °C. For BC2-Nb association, a flow rate of 50 μl / min was applied for 15 s, and for dissociation, a flow rate of 50 μl / min was applied for 600 s. Regeneration was induced by injecting 23 μl of regeneration solution at a flow rate of 30 μl / min. The regeneration solution consisted of 10 mM glycine-HCl pH 2.0. Data were evaluated using Bia Assessment 4.1 software and a 1:1 Langmuir binding model with mass transfer.

[0246] SDS-PAGE and immunoblotting

[0247] Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to standard procedures. Protein samples were boiled in 2×SDS-sample buffer (60 mM Tris / HCl, pH 6.8; 2% (w / v) SDS; 5% (v / v) 2-mercaptoethanol, 10% (v / v) glycerol, 0.02% bromophenol blue). For immunoblotting, proteins were transferred onto nitrocellulose membranes (Bio-Rad Laboratories).

[0248] Antibody

[0249] For immunoblotting, the following primary antibodies were used: anti-GFP clone 3H9 (ChromoTek), anti-PCNA clone 16D10 (ChromoTek), anti-Vimentin clone V9 (Sigma Aldrich), anti-GAPDH (abcam), and anti-β-linkin clone 14 (BD-Biosciences). For assays, species-specific secondary antibodies labeled with fluorophores were used (Alexa-647, goat-anti-rabbit, goat-anti-rat; goat-anti-mouse Life Technologies). Blots were scanned using a Typhoon-Trio laser scanner (GE Healthcare).

[0250] Immunoprecipitation of BC2-labeled proteins

[0251] Transient expression of eGFP, eGFP BC2T or BC2T eGFP, eGFP-PCNA, eGFP-PCNA BC2T mCherry-Vimentin BC2THEK293T cells were washed and harvested in phosphate-buffered saline (PBS), flash-frozen in liquid nitrogen, and stored at -20°C. Cell pellets were homogenized in 200 μl of lysis buffer (10 mM Tris / Cl pH 7.5, 150 mM NaCl, 0.5% NP40, 1 μg DNase I, 2 mM MgCl2, 2 mM PMSF, 1× protease inhibitor mixture M (Serva)) by repeated aspiration on ice for 40 min. Following centrifugation (18,000×g for 10 min), protein concentrations of each lysate were determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) according to the manufacturer's protocol, and the protein solutions were adjusted to a concentration of 1 mg / mL using dilution buffer (10 mM Tris / Cl pH 7.5, 150 mM NaCl, 2 mM PMSF). 2% of the supernatant was added to sample buffer containing SDS (referred to as input). Add 50 μl of BC2 nanotrap (slurry) / 100 μl of supernatant, then incubate at 4 °C on an end-over-end rotor for 1 h. After centrifugation (2 min, 2500 × g), transfer the pre-cleaned supernatant to a new vessel. Add 2% to sample buffer containing SDS (referred to as unbound). After four washes, elute the BC2 nanotrap-bound proteins by boiling the beads in 50 μl of SDS-sample buffer or by incubation with the indicated elution buffer. Analyze the sample by SDS-PAGE followed by Western blotting. Detect the Western blotting using the indicated antibody.

[0252] Immunoprecipitation under harsh conditions

[0253] For each condition, 50 μl of bead-slurry was mixed with 100 μl of soluble protein fraction from *E. coli* lysate (c = 1 mg / ml) and 150 μl of solution containing a detergent or dissociation agent, resulting in the final concentration indicated below. Urea (0M, 1M, 2M, 4M) and guanidine hydrochloride (0M, 0.375M, 0.75M, 1.5M, 3M) were used as dissociation agents, and SDS (0%, 0.1%, 0.5%, 1%, 2%) was used as a detergent. After incubation at 4°C on an inverted vortex mixer for one hour and centrifugation (2 min, 2500×g, 4°C), the supernatant was discarded, and the remaining beads were washed twice in PBS before boiling in 50 μl of 2× sample buffer. The (B) fraction of each bead binding was analyzed by SDS-PAGE and Western blotting using anti-GFP antibody.

[0254] Elution of bound BC2-labeled proteins

[0255] For the elution experiment, use GFP derived from expression. BC2T 400 μl of soluble protein extract (c = 1 mg / ml) from *E. coli* cells was incubated with 40 μl of BC2 nanotraps (slurry) at 4 °C on an inverted vortex mixer for 1 h. After centrifugation (2500 × g, 4 °C, 2 min), the supernatant was discarded and the beads were washed four times in ice-cold PBS after a second wash, including cup changes. Subsequently, the beads were precipitated and incubated at RT for 15 min using 80 μl of the indicated elution conditions. The following elution conditions were tested: Peptide elution: 0 mM, 0.01 mM, 0.1 mM, or 1 mM BC2-peptide dissolved in 0.2 M Tris / Cl pH 7.4, 150 mM NaCl; Acidic elution: 0.2 M glycine-HCl adjusted to pH 1, pH 2, or pH 3; Alkaline elution: 0 mM, 1 mM, 10 mM, or 100 mM NaOH; Elution using sodium thiocyanate: 0 M, 1 M, 2 M, or 3 M NaSCN. The eluent was collected and boiled in 1× SDS containing sample buffer, and the remaining beads were washed twice in PBS before boiling in 40 μl of 2× sample buffer. 10% of each elution (release, R) and bead-bound (bound, B) fractions were analyzed by SDS-PAGE and Western blotting using anti-GFP antibody.

[0256] Immunofluorescence staining using fluorescently labeled nanobodies

[0257] Purified BC2 nanobodies (1 mg) were labeled with the NHS-activated fluorescent dye Alexa488 (Life Technologies) or Atto647 (Atto-Tec) according to the manufacturer's instructions. Unbound dye was removed after conjugation by separation on PD-10 Desalting Columns (GE Healthcare). For immunoblotting analysis, 5 μg of BC2-Nb was used. AF488 The protein blot was diluted in 4 ml of 3% BSA with TBS and 0.05% Tween 20, and cultured at RT for 1 h.

[0258] For immunocytochemistry, transfection with plasmids encoding C-terminal BC2-labeled vimentin or PCNA at a concentration of 5-10 × 10⁶ cells / mL is performed. 3Adherent HeLa cells were placed in the wells of a μClear 96-well (Greiner) plate. After 24 h, cells were washed once with PBS and fixed at RT for 15 min with 4% w / v paraformaldehyde (PFA) in PBS or at -20°C for 15 min with methanol. After removing the fixative and washing twice with PBS, cells were blocked and permeabilized at RT for 1 h with 3% w / v BSA and 0.1% v / v Triton X-100 in PBS. Subsequently, labeled BC2 nanobodies and 4',6-diamidinyl-2-phenylindole (DAPI, Sigma Aldrich) at a final concentration of 10–15 μg / ml were added, and the cells were incubated overnight at 4°C. Unbound nanobodies and DAPI were removed by washing three times with a mixture of 6% v / v 5M NaCl in PBS and H2O. The cells were obtained using the Image Xpress micro XL system. Figure 4 b and Figure 10 Image of b. Figure 10 The confocal image of a was obtained using ImageXpress Micro Confocal.

[0259] Fluorescence spectroscopy

[0260] Fluorescence analysis was performed by scanning a 96-well microplate (Nunc) on a Typhoon Trio (GE Healthcare Life Sciences) with excitation at 488 nm and emission filter set to 520 nm BP 40.

[0261] Biological layer interferometry

[0262] Affinity measurements of BC2-Nb for BC2T and modified variants pTag1 and pTag2 were performed using the BLItz system instrument (fortéBIO) via biolayer interferometry. BC2T and its variant biotinylated peptides were immobilized on streptavidin biosensors (fortéBIO). The loaded sensors were sequentially immersed in BLItz buffer (phosphate-buffered saline, 0.1% (m / v) BSA, 0.02% (v / v) Tween 20) for 120 s to measure baseline signal, in a solution of BC2-Nb in BLItz buffer (5–50 nM concentration) for 120 s to measure association, and in BLItz buffer for 600 s to measure dissociation. The vibration rate was 1200 rpm. As a reference, each peptide was also cultured using BLItz buffer according to the above protocol only. In the control experiment, streptavidin biosensors were cultured using BC2-Nb without prior peptide immobilization. The sensor was regenerated by continuous immersion in 10 mM glycine pH 2.0 and BLItz buffer (repeated three times). Raw data were analyzed using BLItz Pro (fortéBio) software and a 1:1 binding model.

[0263] References

[0264] 1 De Genst,E.et al.Molecular basis for the preferential cleftrecognition by dromedary heavy-chain antibodies.Proceedings of the National Academy of Sciences of the United States of America 103,4586-4591,doi:10.1073 / pnas.0505379103(2006).

[0265] 2 Muyldermans, S. Single domain camel antibodies: current status. Journal of biotechnology 74, 277-302 (2001).

[0266] 3 Govaert,J.et al.Dual beneficial effect of interloop disulfide bondfor single domain antibody fragments.The Journal of biological chemistry 287,1970-1979,doi:10.1074 / jbc.M111.242818(2012).

[0267] 4 Rothbauer,U.et al.A versatile nanotrap for biochemical andfunctional studies with fluorescent fusion proteins.Molecular&cellularproteomics:MCP 7,282-289,doi:10.1074 / mcp.M700342-MCP200(2008).

[0268] 5 Muyldermans,S.Nanobodies:natural single-domain antibodies.Annu RevBiochem 82,775-797,doi:10.1146 / annurev-biochem-063011-092449(2013).

[0269] 6 Lee,S.Y.et al.Ube3a,the E3 ubiquitin ligase causing Angelmansyndrome and linked to autism,regulates protein homeostasis through theproteasomal shuttle Rpn10.Cellular and molecular life sciences:CMLS 71,2747-2758,doi:10.1007 / s00018-013-1526-7(2014).

[0270] 7 Schembri,L.et al.The HA tag is cleaved and loses immunoreactivityduring apoptosis.Nature methods 4,107-108,doi:10.1038 / nmeth0207-107(2007).

[0271] 8 Wegner,G.J.,Lee,H.J.&Corn,R.M.Characterization and optimization ofpeptide arrays for the study of epitope-antibody interactions using surfaceplasmon resonance imaging.Analytical chemistry 74,5161-5168(2002).

[0272] 9 Hilpert,K.et al.Anti-c-myc antibody 9E10:epitope key positions andvariability characterized using peptide spot synthesis on cellulose.ProteinEng 14,803-806(2001).

[0273] 10 De Genst,E.J.et al.Structure and properties of a complex of alpha-synuclein and a single-domain camelid antibody.Journal of molecular biology402,326-343,doi:10.1016 / j.jmb.2010.07.001(2010).

[0274] 11 Traenkle,B.et al.Monitoring interactions and dynamics ofendogenous beta-catenin with intracellular nanobodies in livingcells.Molecular&cellular proteomics:MCP,doi:10.1074 / mcp.M114.044016(2015).

[0275] 12 Huang,L.et al.SPECT imaging with 99mTc-labeled EGFR-specificnanobody for in vivo monitoring of EGFR expression.Molecular imaging andbiology:MIB:the official publication of the Academy of Molecular Imaging 10,167-175,doi:10.1007 / s11307-008-0133-8(2008).

[0276] 13 Vaneycken,I.et al.Preclinical screening of anti-HER2 nanobodiesfor molecular imaging of breast cancer.FASEB journal:official publication ofthe Federation of American Societies for Experimental Biology 25,2433-2446,doi:10.1096 / fj.10-180331(2011).

[0277] 14 Broisat,A.et al.Nanobodies targeting mouse / human VCAM1 for thenuclear imaging of atherosclerotic lesions.Circulation research 110,927-937,doi:10.1161 / CIRCRESAHA.112.265140(2012).

[0278] 15 Ries,J.,Kaplan,C.,Platonova,E.,Eghlidi,H.&Ewers,H.A simple,versatile method for GFP-based super-resolution microscopy viananobodies.Nature methods 9,582-584,doi:10.1038 / nmeth.1991(2012).

[0279] 16 Yoon,M.,Moir,R.D.,Prahlad,V.&Goldman,R.D.Motile properties ofvimentin intermediate filament networks in living cells.The Journal of cellbiology 143,147-157(1998).

[0280] 17 Leonhardt,H.et al.Dynamics of DNA replication factories in livingcells.The Journal of cell biology 149,271-280(2000).

[0281] 18 Maier,J.,Traenkle,B.&Rothbauer,U.Real-time analysis of epithelial-mesenchymal transition using fluorescent single-domain antibodies.Scientificreports 5,13402,doi:10.1038 / srep13402(2015).

[0282] 19 Kirchhofer,A.et al.Modulation of protein properties in livingcells using nanobodies.Nature structural&molecular biology 17,133-138,doi:10.1038 / nsmb.1727(2010).

[0283] 20 Kabsch,W.Xds.Acta crystallographica.Section D,Biologicalcrystallography 66,125-132,doi:10.1107 / S0907444909047337(2010).

[0284] 21 McCoy,A.J.et al.Phaser crystallographic software.Journal ofapplied crystallography 40,658-674,doi:10.1107 / S0021889807021206(2007).

[0285] 22 Winn,M.D.et al.Overview of the CCP4 suite and currentdevelopments.Acta crystallographica.Section D,Biological crystallography 67,235-242,doi:10.1107 / S0907444910045749(2011).

[0286] 23 Stein,N.CHAINSAW:a program for mutating pdb files used astemplates in molecular replacement.Journal of applied crystallography 41,641-643,doi:Doi 10.1107 / S0021889808006985(2008).

[0287] 24 Adams,P.D.et al.PHENIX:a comprehensive Python-based system formacromolecular structure solution.Acta crystallographica.Section D,Biologicalcrystallography 66,213-221,doi:10.1107 / S0907444909052925(2010).

[0288] 25 Murshudov, GN, Vagin, AA & Dodson, EJ Refinement of macromolecular structures by the maximum-likelihood method. Acta crystallographica. Section D, Biological crystallography 53, 240-255, doi: 10.1107 / S0907444996012255 (1997).

[0289] 26 Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta crystallographica. Section D, Biological crystallography 60, 2126-2132, doi: 10.1107 / S0907444904019158 (2004).

[0290] 27 Chen,VBet al.MolProbity:all-atom structure validation formacromolecular crystallography.Acta crystallographica.Section D,Biologicalcrystallography 66,12-21,doi:10.1107 / S0907444909042073(2010). sequence list <110> Colmodeur NMI Institute of Natural Sciences and Medicine, University of Tübingen <120> Epitope labeling and methods for detecting, capturing, and / or purifying labeled peptides <130> CHR161101PCT <150> EP15194838.7 <151> 2015-11-16 <160> 46 <170> BiSSAP 1.3.6 <210> 1 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Epitope peptide <220> <221> variants <222> 2 <223> K or substitution <220> <221> variants <222> 3 <223> A or R, or a conservative permutation of A or R <220> <221> variants <222> 5 <223> V or conservative substitution of V <220> <221> variants <222> 7 <223> H or conservative substitution of H <400> 1 Arg Xaa Xaa Ala Xaa Ser Xaa Trp 1 5 <210> 2 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Epitope peptide <220> <221> variants <222> 2 <223> D or conservative permutation of D <220> <221> variants <222> 4 <223> K or substitution <220> <221> variants <222> 5 <223> A or R, conservative permutation of A or R <220> <221> variants <222> 7 <223> V or conservative substitution of V <220> <221> variants <222> 9 <223> H or conservative substitution of H <220> <221> variants <222> 11 <223> Q or Q's conservative permutation <220> <221> variants <222> 12 <223> Q or Q's conservative permutation <400> 2 Pro Xaa Arg Xaa Xaa Ala Xaa Ser Xaa Trp Xaa Xaa 1 5 10 <210> 3 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Epitope peptide 8 aa <400> 3 Arg Lys Ala Ala Val Ser His Trp 1 5 <210> 4 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Epitope peptide <400> 4 Pro Asp Arg Lys Ala Ala Val Ser His Trp Gln Gln 1 5 10 <210> 5 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Epitope peptide <400> 5 Pro Val Arg Ser Ala Ala Leu Ser Gln Trp Ser Ser 1 5 10 <210> 6 <211> 122 <212> PRT <213> Artificial sequence <220> <223> BC2-Nb <400> 6 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Thr Leu Ser Cys Thr Ala Ser Gly Phe Thr Leu Asp His Tyr 20 25 30 Asp Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Ser Cys Ile Asn Asn Ser Asp Asp Asp Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Phe Met Asp Asn Ala Lys Asp Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Ala Glu Ala Arg Gly Cys Lys Arg Gly Arg Tyr Glu Tyr Asp Phe Trp 100 105 110 Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 <210> 7 <211> 25 <212> PRT <213> Artificial sequence <220> <223> Framework region 1 of BC2-Nb <400> 7 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Thr Leu Ser Cys Thr Ala Ser 20 25 <210> 8 <211> 8 <212> PRT <213> Artificial sequence <220> <223> CDR1 of BC2-Nb <400> 8 Gly Phe Thr Leu Asp His Tyr Asp 1 5 <210> 9 <211> 17 <212> PRT <213> Artificial sequence <220> <223> BC2-Nb frame region 2 <400> 9 Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser 1 5 10 15 Cys <210> 10 <211> 9 <212> PRT <213> Artificial sequence <220> <223> CDR2 of BC2-Nb <400> 10 Ile Asn Asn Ser Asp Asp Asp Thr Tyr 1 5 <210> 11 <211> 39 <212> PRT <213> Artificial sequence <220> <223> BC2-Nb frame region 3 <400> 11 Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Phe Met Asp Asn Ala 1 5 10 15 Lys Asp Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr 20 25 30 Ala Ile Tyr Tyr Cys Ala Glu 35 <210> 12 <211> 14 <212> PRT <213> Artificial sequence <220> <223> CDR3 of BC2-Nb <400> 12 Ala Arg Gly Cys Lys Arg Gly Arg Tyr Glu Tyr Asp Phe Trp 1 5 10 <210> 13 <211> 10 <212> PRT <213> Artificial sequence <220> <223> BC2-Nb frame region 4 <400> 13 Gly Gln Gly Thr Gln Val Thr Val Ser Ser 1 5 10 <210> 14 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Epitope peptide 10 aa <400> 14 Pro Asp Arg Lys Ala Ala Val Ser His Trp 1 5 10 <210> 15 <211> 28 <212> DNA <213> Artificial sequence <220> <223> GFP(BC2T) forward primer <400> 15 gcaccatgga tggtgagcaa gggcgagg 28 <210> 16 <211> 31 <212> DNA <213> Artificial sequence <220> <223> GFP(BC2T) reverse primer <400> 16 gacgtcgact tactgctgcc agtgactaac a 31 <210> 17 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> His6-GFP(BC2T) forward primer <400> 17 cagggatccg agtgagcaag ggc 23 <210> 18 <211> 29 <212> DNA <213> Artificial sequence <220> <223> His6-GFP(BC2T) reverse primer <400> 18 cagggtaccttactgctgcc agtgactaa 29 <210> 19 <211> 25 <212> DNA <213> Artificial sequence <220> <223> GFP BC2Tmut forward primer <400> 19 ggatccgatg gtgagcaagg gcgag 25 <210> 20 <211> 65 <212> DNA <213> Artificial sequence <220> <223> GFP(BC2Tmut) reverse primer <400> 20 ggtaccttag ctgctccact ggctcagcgc cgcgctccgg accggcttgt acagctcgtc 60 catgc 65 <210> twenty one <211> 30 <212> DNA <213> Artificial sequence <220> <223> His6-GFP(BC2T-10) forward primer <400> twenty one ccccggatcc gatggtgagc aagggcgagg 30 <210> twenty two <211> 64 <212> DNA <213> Artificial sequence <220> <223> His6-GFP(BC2T-10) reverse primer <400> twenty two ccccggtacc ttaccaatgt gacaccgctg ctttgcggtc aggcttgtac agctcgtcca 60 tgcc 64 <210> twenty three <211> 30 <212> DNA <213> Artificial sequence <220> <223> His6-GFP(BC2T-8) forward primer <400> twenty three ccccggatcc gatggtgagc aagggcgagg 30 <210> twenty four <211> 56 <212> DNA <213> Artificial sequence <220> <223> His6-GFP(BC2T-8) reverse primer <400> twenty four ccccggtacc ttaccagtgg gaaacggctg ctttacgctt gtacagctcg tccatg 56 <210> 25 <211> 27 <212> DNA <213> Artificial sequence <220> <223> eGFP(BC2T) forward primer <400> 25 aagctagcgc taccggtcgc caccatg 27 <210> 26 <211> 62 <212> DNA <213> Artificial sequence <220> <223> eGFP(BC2T) reverse primer <400> 26 aaggtacctt attgctgcca gtgactaaca gccgcttttc tgtctggctt gtacagctcg 60 tc 62 <210> 27 <211> 51 <212> DNA <213> Artificial sequence <220> <223> NheI - BC2T - BgIII <400> 27 gctagcatgc ccgatcgtaa ggctgcggtc tctcattggc aacagagatc t 51 <210> 28 <211> 41 <212> DNA <213> Artificial sequence <220> <223> mCherry-Vimentin (BC2T) forward primer <400> 28 aaaagcttag gtggaggagg ttcttccacc aggtccgtgt c 41 <210> 29 <211> 62 <212> DNA <213> Artificial sequence <220> <223> mCherry-Vimentin (BC2T) reverse primer <400> 29 aaggtaccct attgctgcca gtgactaaca gccgcttttc tgtctggttc aaggtcatcg 60 tg 62 <210> 30 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> GFP-PCNA(BC2T) forward primer <400> 30 gtatggcttc gtggggatcc ccg 23 <210> 31 <211> 78 <212> DNA <213> Artificial sequence <220> <223> GFP-PCNA(BC2T) reverse primer <400> 31 ggggtctaga ctaaaggtac cctattgctg ccagtgacta acagccgctt ttctgtctgg 60 agatccttct tcatcctc 78 <210> 32 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Epitope peptide <220> <221> variants <222> 1 <223> P or A <220> <221> variants <222> 2 <223> D or conservative permutation of D <220> <221> variants <222> 4 <223> K or substitution <220> <221> variants <222> 5 <223> A or R, or a conservative permutation of A or R <220> <221> variants <222> 7 <223> V or conservative substitution of V <220> <221> variants <222> 9 <223> H or conservative substitution of H <220> <221> variants <222> 11 <223> Q or Q's conservative permutation <220> <221> variants <222> 12 <223> Q or Q's conservative permutation <400> 32 Xaa Xaa Arg Xaa Xaa Ala Xaa Ser Xaa Trp Xaa Xaa 1 5 10 <210> 33 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Epitope peptide <400> 33 Pro Asp Arg Val Arg Ala Val Ser His Trp Ser Ser 1 5 10 <210> 34 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Epitope peptide <400> 34 Ala Asp Arg Val Arg Ala Val Ser His Trp Ser Ser 1 5 10 <210> 35 <211> 50 <212> DNA <213> Artificial sequence <220> <223> mCherry_BC2T_fw <400> 35 gtacagtggt ccggatcgca aagcggcggt gagccattgg cagcagtaaa 50 <210> 36 <211> 50 <212> DNA <213> Artificial sequence <220> <223> mCherry_BC2T_rv <400> 36 agcttttact gctgccaatg gctcaccgcc gctttgcgat ccggaccact 50 <210> 37 <211> 50 <212> DNA <213> Artificial sequence <220> <223> mCherry_SEQ33_fw <400> 37 gtacagtggt ccggatcgcg tgcgcgcggt gagccattgg agcagctaaa 50 <210> 38 <211> 50 <212> DNA <213> Artificial sequence <220> <223> mCherry_SEQ33_rv <400> 38 agcttttagc tgctccaatg gctcaccgcg cgcacgcgat ccggaccact 50 <210> 39 <211> 50 <212> DNA <213> Artificial sequence <220> <223> mCherry_SEQ34_fw <400> 39 gtacagtggt gcggatcgcg tgcgcgcggt gagccattgg agcagctaaa 50 <210> 40 <211> 50 <212> DNA <213> Artificial sequence <220> <223> mCherry_SEQ34_rv <400> 40 agcttttagc tgctccaatg gctcaccgcg cgcacgcgat ccgcaccact 50 <210> 41 <211> 46 <212> DNA <213> Artificial sequence <220> <223> mCherry_BC2T_fw2 <400> 41 tatgccggat cgcaaagcgg cggtgagcca ttggcagcag ggctcg 46 <210> 42 <211> 48 <212> DNA <213> Artificial sequence <220> <223> mCherry_BC2T_rv2 <400> 42 gatccgagcc ctgctgccaa tggctcaccg ccgctttgcg atccggca 48 <210> 43 <211> 46 <212> DNA <213> Artificial sequence <220> <223> mCherry_SEQ33_fw2 <400> 43 tatgccggat cgcgtgcgcg cggtgagcca ttggagcagc ggctcg 46 <210> 44 <211> 48 <212> DNA <213> Artificial sequence <220> <223> mCherry_SEQ33_rv2 <400> 44 gatccgagcc gctgctccaa tggctcaccg cgcgcacgcg atccggca 48 <210> 45 <211> 46 <212> DNA <213> Artificial sequence <220> <223> mCherry_SEQ34_fw2 <400> 45 tatggcggat cgcgtgcgcg cggtgagcca ttggagcagc ggctcg 46 <210> 46 <211> 48 <212> DNA <213> Artificial sequence <220> <223> mCherry_SEQ34_rv2 <400> 46 gatccgagcc gctgctccaa tggctcaccg cgcgcacgcg atccgcca 48

Claims

1. An isolated epitope peptide, Its amino acid sequence is SEQ ID NO:33, or Its amino acid sequence is SEQ ID NO:

34.

2. Use of the epitope peptide of claim 1 as an N-terminal or C-terminal epitope marker.

3. A nucleic acid encoding the isolated epitope peptide as defined in claim 1; wherein the nucleic acid is RNA, DNA, PNA, or LNA.

4. A nucleic acid expression construct comprising at least one nucleic acid as described in claim 3, and a nucleic acid encoding a polypeptide of interest and / or at least one linker.

5. The nucleic acid expression construct of claim 4, further comprising a linker, wherein the linker comprises a nucleic acid sequence encoding a cleavage site or a site recognized by an enzyme adjacent to the nucleic acid localized in claim 3, wherein the cleavage site is recognized by a protease.

6. A host cell comprising a nucleic acid as defined in claim 3, or a nucleic acid expression construct as defined in any one of claims 4 or 5; wherein the host cell is a prokaryotic cell or a eukaryotic cell.

7. The host cell of claim 6, wherein the host cell is a bacterial cell.

8. The host cell of claim 6, wherein the host cell is a plant cell or a fungal cell.

9. The host cell of claim 6, wherein the host cell is a yeast cell.

10. The host cell of claim 6, wherein the host cell is a nematode cell, bird cell, fish cell, insect cell, or mammalian cell.

11. A method for introducing a nucleic acid as defined in claim 3, or a nucleic acid expression construct as defined in any one of claims 4 or 5, into a host cell, wherein the nucleic acid is fused to a nucleic acid encoding a polypeptide of interest in the host cell, the method being selected from CRISPR / Cas genome editing, genome editing methods using zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), or a wide range of nucleases, reagent-based methods using reagents, transduction, transfection, and instrument-based methods such as electroporation, microinjection, and laser transfection.

12. The method of claim 11, wherein the reagent is anionic lipid, calcium phosphate, or DADE-glucan.

13. An in vitro method for determining the presence, subcellular localization, and / or amount of a polypeptide of interest comprising the epitope peptide as defined in claim 1, comprising the following steps: a) Applying an affinity ligand capable of specifically binding the epitope peptide to a sample, a host cell as defined in any one of claims 6-10, or a cell lysate of a host cell as defined in any one of claims 6-10, wherein the affinity ligand comprises a detectable portion; b) Determine the presence, subcellular localization, and / or amount of the polypeptide of interest, including the epitope peptide, by detecting the detectable portion.

14. An in vitro method for determining the presence, subcellular localization, and / or amount of a polypeptide of interest comprising an epitope peptide as defined in claim 1, comprising the following steps: a) Applying an affinity ligand capable of specifically binding the epitope peptide to a sample, a host cell as defined in any one of claims 6-10, or a cell lysate of a host cell as defined in any one of claims 6-10. b) Apply at least a second binding partner capable of binding the affinity ligand, labeled polypeptide, or a complex of both of the described in step a), wherein the second binding partner comprises a detectable portion and / or an immobilized or immobilizable portion. c) Determine the presence, subcellular localization, and / or amount of the polypeptide of interest, including the epitope peptide, by detecting the detectable portion.

15. The method of claim 13 or 14, wherein the detectable portion is a fluorescent tag, wherein the determination is performed by measuring fluorescence levels; or wherein the presence and / or amount of the polypeptide of interest, comprising the epitope peptide, is determined by Western blotting.

16. A method for purifying a polypeptide of interest comprising an epitope peptide as defined in claim 1, wherein the method comprises the following steps a) Contact a sample including the construct or the polypeptide of interest with an affinity ligand capable of specifically binding to the epitope peptide, wherein the affinity ligand is attached to a solid support before or after binding; b) Contact the sample obtained after step a) with a second binding partner capable of binding the affinity ligand, labeled polypeptide, or a complex of both of the one obtained in step a), wherein the second binding partner is attached to a solid support before or after binding. c) Washing the solid support in step a) or b) to remove unbound and non-specifically bound components; and d) Elute the construct or the polypeptide of interest.

17. The method of claim 16, wherein the sample in step a) is a lysate of a host cell defined in any one of claims 6-10, comprising a nucleic acid construct as defined in claim 4 or 5, wherein the method further comprises, after or replacing step e) of claim 16, removing the epitope peptide from the polypeptide of interest by protease cleavage.

18. The method of any one of claims 13, 14, 16 and 17, wherein the affinity ligand is an antibody, wherein the antibody is a fragment of a single-domain antibody, wherein the fragment of the single-domain antibody consists of an amino acid sequence as defined in SEQ ID NO:

6.

19. A kit for capturing and / or detecting peptides, comprising: a) The nucleic acid as defined in claim 3, or the nucleic acid expression construct as defined in any one of claims 4 or 5; b) Specifically binds to an affinity ligand of an epitope peptide as defined in claim 1, wherein the affinity ligand comprises a detectable portion, wherein the detectable portion is a fluorescent tag; wherein the affinity ligand is an affinity ligand as defined in claim 18; c) A second binding pair specific to the affinity ligand, the labeled polypeptide, or a complex of both, wherein the second binding pair comprises a detectable portion and / or an immobilized or immobilizable portion; and d) Buffer solutions and reagents required for the method as defined in any one of claims 13 to 18.

20. A kit for capturing and / or purifying peptides, comprising: a) The nucleic acid as defined in claim 3, or the nucleic acid expression construct as defined in any one of claims 4 or 5; b) Specifically binds to an affinity ligand of the epitope peptide as defined in claim 1, wherein the affinity ligand is attached to a solid support; c) A second binding pair specific to the affinity ligand, the labeled polypeptide, or a complex of both, wherein the second binding pair is attached to a solid support or is immobilizable; and d) The isolated epitope peptide as defined in claim 1; e) a solid support, wherein the solid support is selected from polystyrene, polypropylene, polyvinyl chloride, polyacrylamide, dextran, latex, silica, agarose, metal, glass, and carbon; and f) Buffer solutions and reagents required for the method as defined in any one of claims 13 to 18.

21. The kit of claim 20, wherein the solid support is selected from cellulose.

Citation Information

Patent Citations

  • Antibody for epitope tagging, hybridoma cell line and uses thereof

    CN104812773A

  • Epitope tag for affinity-based applications

    US20130115635A1